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ABSTRACT 
Objectives 
The aim of this systematic review was to identify and synthesise the current research 
investigating the demographic, clinical and psycho-social factors associated with 
anxiety and/or depression symptoms in adults with Cystic Fibrosis (CF).  Anxiety and 
depression symptoms are elevated in the adult CF population compared to the general 
population.  An awareness of the factors associated with anxiety/depression would 
contribute to a better understanding of ‘at-risk’ groups and allow targeted screening and 
early intervention.   
Method 
A systematic search was conducted using PsycINFO, Psychology and Behavioural 
Sciences collection, MEDLINE, EMBASE, and CINAHL.  Studies were screened 
against inclusion/exclusion criteria, with a narrative synthesis of the eligible studies 
conducted.  A study quality tool was adapted for cross-sectional studies and used to 
evaluate included studies.   
Results 
Fourteen articles were included in the review.  Inconsistent results were found for 
factors including age, gender, Body Mass Index (BMI), lung functioning, and work 
status being associated with anxiety/depression.  Consistent associations were found 
between anxiety/depression symptoms and pain and health-related quality of life 
(HRQoL).  Furthermore, depression symptoms were positively associated with anxiety 
symptoms, and vice versa.    
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Conclusions 
The review identified numerous factors that may be associated with anxiety/depression 
symptoms in an adult CF population.  Consistent associations were found between 
anxiety and depression symptoms themselves; and also anxiety/depression symptoms 
and pain and Health Related Quality of Life.  However, there were several limitations of 
the studies including use of cross-sectional designs and limited exploration of 
interaction effects, which prevented definitive conclusions from being drawn.  Future 
research should address these limitations, seek to replicate findings of single studies and 
consider the development of a CF specific measure of psychological distress.  
Keywords: adult, cystic fibrosis, psychological distress, socio-demographic factors, 
clinical health factors, systematic review 
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INTRODUCTION 
Cystic Fibrosis (CF) is an inherited, progressive and life-limiting condition in which the 
lungs and digestive system can become obstructed by thick, sticky mucus.  Despite 
advances in diagnosis and treatment, management of CF is complex and individuals can 
experience frequent infections and progressive failure of most organ systems.  Similar 
to other chronic physical health conditions, adults with CF are at higher risk for 
experiencing depression and anxiety compared to community samples without chronic 
health conditions (Quittner et al., 2014).  Research has shown that prolonged 
psychological difficulties in patients with chronic illnesses can be associated with poor 
treatment adherence (Grenard et al., 2011) and increased healthcare costs (Snell et al., 
2014).  
Following these findings, recommendations were made to introduce annual screening of 
patients with CF for symptoms of depression/anxiety, so that those affected received 
timely further assessment and treatment (Quittner et al., 2014).  This was further 
endorsed by the European Cystic Fibrosis Society’s Standards of Care (Smyth et al., 
2014), with guidelines being published by the International Committee on Mental 
Health in Cystic Fibrosis (Quittner et al., 2016) stating that annual screening should be 
conducted by healthcare professionals, preferably mental health specialists.  Although 
this appears to be reasonable Abbott et al. (2015) had highlighted that limited staff 
numbers/time were significant barriers to implementing a mental health screening 
programme.  
In order to maximise the potential benefit of a screening programme, with limited 
resources, it may be beneficial to screen ‘at-risk’ populations. This would allow early 
identification of individuals who may be more likely to experience anxiety/depression 
and allow preventative measures to be implemented to reduce the likelihood of 
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experiencing anxiety/depression symptoms.  Furthermore, it would also allow for early 
intervention to be provided to those already experiencing anxiety/depression symptoms 
with the aim of reducing the negative impact of these psychological difficulties. To 
date, there has been no review of the risk factors associated with anxiety/depression 
symptoms in an adult CF population.  However, risk factors have been identified in 
other chronic health conditions and reported in a substantial review by Clarke and 
Currie (2009); for example, risk factors for depression following a stroke included 
social isolation, functional/cognitive impairment, and past history of depression.  In 
cancer, risk factors for depression included younger age, pain and helpless coping style. 
It is evident that risk factors for anxiety/depression in chronic health conditions can be 
categorised under health, demographic and psycho-social factors.  As CF is a chronic 
condition it is likely that some of these factors would also be associated with 
anxiety/depression in this population.    
It is important to highlight that although anxiety/depression are focused upon in the 
literature it has been argued that the term ‘distress’ is more favourable as this is 
considered to be a non-stigmatising term that describes the psychological reaction to 
broad array of difficulties that individuals with physical health conditions can 
experience (Holland, 1997).  These difficulties can range from physical health 
symptoms to treatment adherence problems to end of life considerations.  Although 
these difficulties may not map directly onto psychopathology measures, they are 
important to acknowledge and may have overlap with anxiety/depression symptoms.   
To date the majority of research regarding the well-being of individuals with CF has 
focused on Health Related Quality of Life (HRQoL) which aims to capture a broader 
conceptualisation of health.  A systematic review by Habib et al. (2015) investigated 
factors associated with HRQoL in CF, reporting that clinical characteristics such as 
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poorer lung function were negatively associated with HRQoL.  Recommendations were 
made to further investigate/review the relationship of these potential factors on 
psychological well-being. 
Several individual studies have investigated these relationships but, to date, no 
systematic review has synthesised the available evidence.  Such a synthesis has the 
potential to improve the input of psychological services in adults with CF. Identifying 
factors associated with anxiety/depression could highlight ‘at-risk’ groups, thereby 
driving the development of targeted screening tools. This potential facilitation of earlier 
intervention could limit negative impact on health outcomes.  Therefore, this review 
aimed to identify and synthesise the current research investigating health, demographic 
and psycho-social factors associated with anxiety and/or depression in an adult CF 
population.  
METHODS 
Search Strategy 
A search strategy was devised to identify all studies examining anxiety/depression in an 
adult CF population.  Five databases were used in the search (PsycINFO, Psychology 
and Behavioural Sciences Collection, MEDLINE, EMBASE, and CINAHL) from 
inception to 26th October 2018.   Subject headings for each database were identified and 
combined with keyword text (Appendix 2, p.69).  The term ‘distress’ was included in 
the search terms to ensure that all studies relevant to anxiety/depression were detected.  
However, only studies specifically measuring anxiety/depression symptoms were 
included in the current review as these are the most prominently measured constructs in 
the current CF literature. Reference lists of selected articles were also hand-searched for 
additional studies.   
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Study Selection 
All database search results were collated and duplicates removed.  Titles and abstracts 
were screened and selected for full-article review using the criteria in Table 1. The same 
criteria were used during full-article review.  Quantitative data referred to articles 
presenting original, numerical data.  Review papers were excluded to reduce the risk of 
including the same article twice. The search, screening and extraction of articles were 
done by one person. 
Table 1. Inclusion/Exclusion criteria 
Inclusion Exclusion 
• Participant had diagnosis of CF 
and aged≥18 
• Specifically measured anxiety 
and/or depression and reported 
associations with any of the 
proposed factors 
• Published in English in a peer-
reviewed journal 
• Presented primary quantitative data 
• Focused exclusively on HRQoL 
• Measures anxiety and/or 
depression in family 
members/caregivers 
• Review paper 
• Qualitative paper 
 
Data Extraction and Quality Appraisal 
A data extraction table was used to standardise extraction of information across studies, 
recording information such as study design, data analysis, sample characteristics, 
measurement tools and relevant results (Appendix 3, p.70).   
Study quality was assessed using a quality appraisal tool developed by the researcher 
based on the Quality Assessment Tool for Observational Cohort and Cross-Sectional 
Studies (National Heart, Lung and Blood Institute, 2014), the Appraisal Tool for Cross 
Sectional Studies (AXIS) (Downes et al., 2016), the Cohort Study Checklist by Critical 
Appraisal Skills Programme (2018) and previous research (Kolte, 2018).  A checklist of 
items was divided into sections including ‘Quality of Reporting’ and three sources of 
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bias: ‘Selection Bias’, ‘Information Bias’, and ‘Confounding Bias’.  Each domain was 
rated as ‘low’, ‘moderate’ or ‘high’.  An overall study quality rating was given using the 
following criteria: 
• High quality = low risk of bias in all domains, or moderate risk of bias in only 
one domain 
• Moderate quality = moderate risk of bias in at least two domains 
• Low quality = high risk of bias in at least one domain  
50% of included papers were also quality assessed by another Trainee Clinical 
Psychologist.  The agreement rate between assessors was 92%, with any disagreements 
discussed/resolved by consensus.   
Data Synthesis  
Due to the heterogeneity of the proposed factors associated with psychological distress 
and the broad nature of the research question, meta-analysis was not appropriate; 
consequently a narrative synthesis was conducted.  To avoid potentially spurious 
findings from conclusions drawn on examination of single studies, synthesis of results 
required examined factors to be present in at least two papers.  An exception for one 
paper was retrospectively made as it was deemed important to include due to the 
substantial international sample population.   
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RESULTS 
Study selection 
Figure 1 illustrates the study selection process.  The literature search initially yielded 
2303 papers, with removal of duplicates leaving 1467 articles.  Using the 
inclusion/exclusion pre-defined criteria, 1393 articles were excluded following 
screening of the title/abstract.  The most common reasons for exclusion were no specific 
measurement of anxiety/depression and participant age.  Of the remaining 74 articles, 
13 were eligible for inclusion in the narrative synthesis. One further paper was found 
through hand-searching of references.  The total number of eligible papers included in 
the narrative synthesis was 14. 
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Figure 1. PRISMA Flow diagram of study selection process 
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Study Characteristics 
Table 2 presents the 14 studies included in the review.   Eight studies originated from 
the USA and Canada (Anderson et al., 2001; Burker et al., 2004; Hayes et al., 2011; 
Kopp et al., 2013; Maras et al., 2018; Pakhale et al., 2015; Quon et al., 2015; and 
Riekert et al., 2007); four from Europe (Delelis et al., 2008; Havermans et al., 2008; 
Knudsen et al., 2016; and Mengistu et al., 2012) and one from Australia (Burge et al., 
2015).  One study (Quittner et al., 2014) collated data from nine countries across Europe 
and USA.   All studies presented cross-sectional data. Sample sizes varied from 16 to 
183 across 13 of the studies, with one study (Quittner et al., 2014) having a sample size 
of 4739.  Mean ages ranged from 24.1 to 30.7 years, with the majority of studies having 
a relatively even split in participant gender.  One study (Burge et al., 2015) used only 
male participants.  A variety of measures were used to screen for anxiety/depression but 
all were self-report measures.  The percentage of participants scoring above clinical cut-
off points on respective measures ranged from 7-50% for depression and 5-31% for 
anxiety.  Studies used a variety of statistical tests depending upon their aims, including 
correlation, t-test, ANOVA, MANOVA and regression. Effect sizes were reported if 
available. All studies reported associations between depression and/or anxiety 
symptoms and a variety of health, demographic or psycho-social factors.   
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Table 2. Summary of studies included in systematic review 
Study and 
Country 
Sample 
Characteristics 
Factors 
Investigated 
Relevant Results 
Anderson 
et al. 
(2001) 
 
USA 
 
N = 34  
20 Male, 14 
Female 
Age (M=28.5 ± 
8.0) 
 
 
Psychological  
BDI 
STAI 
MMPI  
 
Other factors 
Psychosocial 
support 
Locus of Control  
Physical Health  
Demographic 
 
Age 
• No significant difference in BDI (<27age=5.4 v >27age=5.7) or STAI (<27age=33.8 v >27age=35.6) 
Gender 
• Significant main effect on BDI (Wilks A, 0.66, F=2.95, p<0.05)  
• male gender (M=6.5) associated with higher scores on BDI than female gender (M=4.1) (F=6.16, p<0.05)  
• Trend for STAI score - men (M=37.4) reporting higher levels of anxiety than women (M=31.2) 
(F=3.50;p=0.07)   
Physical Health 
• FEV1% and IBW did not predict BDI scores  
• FEV1% predicted STAI scores - individuals with more impaired lung functioning reported increased anxiety 
(F=6.32, p<0.01) 
• IBW predicted STAI scores - individuals with subnormal body weight reported significantly lower levels of 
anxiety than those with body weights within normal range (F=17.27, p<0.001) 
Psychosocial support 
• Increased psychosocial support predicted lower BDI scores (B=-0.47; t=-3.01; p<0.01) 
Locus of Control 
• No significant findings  
 
Burge et 
al. (2015) 
 
Australia 
N = 160 
(CF=80; Control 
= 80) 
 
All male 
 
Age(CF mean = 
30 SD=8; control 
mean = 31, SD=8) 
 
Psychological  
HADS 
 
Other factors 
ICIQ 
ICIQ-MLUTS 
 
 
 
UI 
• Men with CF and urinary infection had significantly higher scores for anxiety (p=0.003;  d=0.98) and 
depression (p=0.002;  d=1.00) than those without urinary infection. 
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Study and 
Country 
Sample 
Characteristics 
Factors 
Investigated 
Relevant Results 
Burker et 
al. (2004) 
 
USA 
N=183  
91 male 92 female 
 
Age (working 
M=28.6, SD=7.3; 
not working 
M=27.7, SD=8.1) 
 
Psychological  
STAI 
BDI 
 
Other factors 
Type of 
work/number of 
hours worked 
 
Work 
• Those who were working (M=7.84) had significantly lower BDI scores than those who were not working 
(M=12.2) (t=3.45 (133), p<0.001). 
• No significant difference found for state/trait anxiety.  
• Fewer number of hours worked was associated with higher scores on BDI (r=-0.278, p=0.001), but not with 
trait/state anxiety.  
 
Delelis et 
al. (2008) 
 
France 
N = 16  
8 male 8 female 
 
Age (M=28 
±4.56) 
Psychological  
STAI 
CES-D 
 
Other factors 
DAS 
WCC  
Disease severity  
Marital Adjustment 
• Significant negative association with depression (r=-0.62, p<0.01) and anxiety (r=-0.55, p<0.05) 
Coping 
• Significant positive association between emotion-focused coping and depression (r=0.78, p<0.01) and anxiety 
(r=0.73, p<0.01).  
Disease severity 
• No difference in anxiety/depression ratings between those with major v minor rating of disease severity  
Anxiety/Depression 
• Significant positive correlation between anxiety and depression (r=0.86, p<0.001) 
 
Haverman
s et al. 
(2008) 
 
Belgium 
N=57 
29 male 28 female 
 
Age 
(M=26.7,SD=8.1) 
Psychological 
HADS 
 
Other 
CFQ-R  
Physical Health 
Health Related Quality of Life (HRQoL) 
• After controlling for lung function, patients with anxiety symptoms had significantly poorer HRQoL scores for 
variety of domains on the CFQ (F statistic ranges from 4.57 – 8.99).  
• Those with depressive symptoms reported significantly lower HRQoL scores for emotional functioning, eating 
disturbance and body image on the CFQ-R (F statistic ranges from 5.41 – 11.81) 
FEV1% 
• No significant association with anxiety/depression.    
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Study and 
Country 
Sample 
Characteristics 
Factors 
Investigated 
Relevant Results 
Hayes et 
al. (2011) 
 
USA 
N=83 
36  Male 47 
Female  
 
Age (Median = 
29.3, range 19-71) 
Psychological 
HADS 
 
Other 
BPI 
PCS 
CFQ-R 
Physical Health  
 
 
Pain 
• Significantly higher depression scores in those with pain in the past 7 days (M=6.2) than those with no pain 
(M=4.9) p=0.03.  
• Significantly higher anxiety scores in patients with pain in the past 7 days (M=8.3) than those with no pain 
(M=6.9) p=0.04. 
• Increased levels of composite pain score significantly correlated with depression (r=0.43, p=0.0003) and 
anxiety (r-0.31, p=0.008). 
 
Knudsen 
et al. 
(2016) 
 
Denmark 
 
N=67 
29 male 38 
females 
 
Age (M=24.1 
range:18-30) 
Psychological 
MDI 
 
Other 
MMAS-8 
CFQ-R 
Socio-
demographic 
Gender 
• Females more likely to report symptoms of depression on the MDI, with a female/male OR of 5:1 (95% CI 
1.03-25.3) for moderate-severe depression.  
Age/Relationship Status/Education/Work Ability 
• Logistic regression results not reported. 
Adherence 
• Negative association with depression ( r=-0.412, p<0.001) 
Health Related Quality of Life  
• Significantly higher CFQ-R total scores for those who had ‘no depression’ (MDI <19) v those who ‘mild 
depression’ (MDI 20<24) on various domains of CFQ-R (Majority of effect sizes, cohen’s  d were large 
ranging from -0.39 to -1.72) 
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Study and 
Country 
Sample 
Characteristics 
Factors 
Investigated 
Relevant Results 
Kopp et al. 
(2013) 
 
USA 
 
 
 
N=30 
19 male 11 
females 
 
Age (M=26.1 ± 
7.0) 
 
 
Psychological 
CES-D 
 
Other 
Actiwatch 2 
memory  
Physical Health  
Length of Stay in 
hospital 
Quality of Life 
Light exposure/ FEV1%/ Quality of Life 
• No significant difference in cumulative light exposure, FEV1%, or Quality of Life between depressed and 
non-depressed subjects.  
Increase length of stay in hospital 
• Significant increase in length of stay for depressed CF patients (15.4 days ) compared to non-depressed CF 
patient (11.7 days), p=0.032) 
  
Maras et 
al. (2018) 
 
Canada 
N=45 
26 male 19 female 
 
Age (M=30.73 
SD=10.80) 
 
 
 
 
 
 
 
 
Psychological 
CES-D 
GAD-7 
 
Other 
Socio-
demographic 
Physical Health 
Pains -CFSS 
BCS 
CFQ 
 
Age/Sex/FEV1% 
• No significant correlation with depression/anxiety 
Pain/Breathlessness Catastrophising (BC) 
• Significant positive correlation between pain and depression (r=0.454, p=0.002) and pain and anxiety 
(r=0.406, p0.006).  
• Significant positive correlation between BC and depression (r=0.433, p=0.003) and BC and anxiety (r=0.389, 
p=0.008) 
CFQ 
• Significant negative correlation with depression (r=-0.580, p<0.001) and anxiety (r=-0.428, p=0.003) 
Anxiety/Depression 
• Significant positive correlation between anxiety and depression (r=0.745, p<0.001) 
 
 
 
 
 
17 
 
Study and 
Country 
Sample 
Characteristics 
Factors 
Investigated 
Relevant Results 
Mengistu 
et al. 
(2012) 
 
UK 
N = 121 
65 male 46 female 
 
Age (M=30 ±8.8) 
 
  
Psychological 
HADS 
 
Other 
CFQ-R 
Physical health 
Socio-
demographic 
Gender 
• Weak positive association between depression and males (r=0.17, p=0.05) but not in regression model 
Age 
• Weak positive association between depression and older age (r=0.18, p=0.04) but not in regression 
• Significant positive association between anxiety and age (r=0.21, p=0.02), accounting for 2% of variance 
(β=0.20, t=2.22, p=0.03) 
BMI 
• Significant independent association with depression β=-0.45, t=2.5, p=0.01) accounting for 8% of the variance 
FEV1% 
• Significant independent association with depression β=-0.49, t=-2.7, p=0.01), accounting for 13% of the 
variance 
CFQ-R 
• Significant independent association with depression (β=-0.51, t=-3.4, p<0.002), accounting for 23% of the 
variance 
• Interpersonal Relationships→  significant independent association with anxiety score ( β=-0.42, t=-4.21, 
p<0.001 accounting for  15% of variance 
• Chest symptoms → significant independent association with anxiety score (β=-0.49 t=-4.73, p<0.001) 
accounted for 9% of variance  
Hospital Readmission Score 
• Significant positive correlation with depression (r=0.40, p<0.001) and anxiety(r=0.25, p=0.01) 
Pakhale et 
al. (2015) 
 
Canada 
 
 
N=45 
26 male 19 female 
Age (M=30.7 
±10.8) 
Psychological 
CES-D 
GAD-7 
 
Other 
Physical health 
Psychological 
Needs  
Access to psychological services 
• Past access to psychological services in CF care was not significantly related to participants’ levels of 
depression (unadjusted p=0.753, φ=0.11) and anxiety (unadjusted p=0.325, φ=0.20)  
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Study and 
Country 
Sample 
Characteristics 
Factors 
Investigated 
Relevant Results 
Quittner et 
al.(2014) 
 
Europe 
and USA 
N=4739 
2468 male 
2271 female 
 
Age (M=28.87 
SD=9.5) 
 
Psychological 
HADS 
CES-D 
 
Other 
Demographic 
Physical health 
Age 
• Older age significantly associated with depression p<0.001 (OR=1.03, 95% CI, 1.02-1.04) and anxiety 
p<0.001(OR=1.02, 95% CI, 1.01-1.03) 
Gender 
• Not associated with depression but female gender significantly associated with anxiety p<0.001 (OR=1.66, 
95% CI, 1.46-1.88) 
BMI 
• Not associated with depression but lower BMI significantly associated with anxiety  
        p=0.003 (OR=1.03 95% CI 1.01-1.05) 
FEV1% 
• Lower FEV1% significantly associated with depression p<0.001 (OR=0.90, 95% CI, 0.88-0.93) and anxiety 
p=0.002 (OR=0.96, 95%CI, 0.93-0.98) 
Anxiety/Depression 
• Adults reporting anxiety 13.64 times more likely to report elevated depression 
 
Haemoptysis/Pneumothorax 
• Significantly associated with depression p<0.001 (OR=1.62, 95%CI, 1.33-1.98) and anxiety p<0.001 
(OR=1.38, 95% CI, 1.15-1.65) 
Transplant 
• Significantly associated with depression p=0.03 (OR=1.39, 95%CI, 1.03-1.87)  and anxiety p=0.039  
(OR=1.34, 95% CI, 1.01-1.77) 
Currently on psychiatric medications 
• Significantly associated with depression p<0.001 (OR=3.56, 95% CI, 2.86-4.42) and anxiety p<0.001 
(OR=3.37, 95%CI,  2.74-4.14) 
Currently receiving psychotherapy 
• Significantly associated with depression p<0.001 (OR=3.21, 95%CI, 2.54-4.06) and anxiety p<0.001 
(OR=4.22, 95%CI, 3.37-5.30) 
Antibiotics 
• Significantly associated with depression p<0.001 (OR=1.65, 95% CI, 1.33-2.04) but not anxiety 
 
 
19 
 
Study and 
Country 
Sample 
Characteristics 
Factors 
Investigated 
Relevant Results 
Quon et al. 
(2015) 
 
USA 
N=153 
77 male 76 female 
 
Age (M=28.6, SD 
= 8.8) 
Psychological 
GAD-7 
PHQ-9 
 
Other 
Socio-
demographic 
Physical health 
Age/Gender/Age of CF diagnosis/BMI/Diabetes/Employment status/Relationship status 
• No association with depression/anxiety 
FEV1% 
• Individuals with higher FEV1% had statistically significant lower depression symptom scores (β=-0.04, 
p=0.04) 
Riekert et 
al. (2007) 
 
USA 
N=76 
34 male 42 female 
 
Age (M=30.6 
SD=9.6) 
 
Psychological 
BDI 
 
Other 
CFQ-R 
Physical Health 
FEV1% 
• Significant negative association with higher depressive symptoms (rho=-0.25, p<0.05) 
• Participants with poor lung function were 3 times more likely (p=0.05, OR=3, 95% CI, 1.0-9.2) to screen 
positively (BDI≥10) for depression than those with better lung function  
HRQoL 
• Higher depressive symptoms significantly negatively correlated with all CFQ-R subscales  (rho = -0.23 to -
0.74) 
• Association between depressive symptoms and CFQ scales was maintained regardless of lung function (rho 
continues to be within medium to large range) 
• Participants with depressive symptoms had significantly lower HRQoL scores on all CFQ subscales than those 
participants without depressive symptoms 
Key: BCS = Breathlessness Catastrophising Scale; BDI = Beck Depression Inventory; BPI = Brief Pain Inventory; CES-D = Centre of Epidemiologic Studies 
– Depression scale; CFQ-R = Cystic Fibrosis Questionnaire – Revised;  CFSS = Cystic Fibrosis Stress Scale; DAS = Dyadic Adjustment Scale;  FEV1 = 
Forced Expiratory Volume; GAD-7 = Generalised Anxiety Disorder – scale; HADS = Hospital Anxiety and Depression Scale; IDIQ = International 
Consultation on Incontinence Questionnaire; IBW = Ideal Body Weight; IDIQ-MLUTS = International Consultation on Incontinence Questionnaire Male 
Lower Urinary Tract Symptoms;  MDI = Major Depression Inventory; MMAS-8 = Morisky Medication Adherence Scale; MMPI = Minnesota Multiphasic 
Personality Inventory; PCS = Pain Catastrophising Scale; PHQ-8= Personal Health Questionnaire Depression Scale; STAI = State-Trait Anxiety Inventory; WCC = 
Ways of Coping Checklist 
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Summary of Study Quality and Risk of Bias 
Quality ratings and risk of bias are summarised in Table 3.  Eight studies were deemed 
‘high’ quality (Anderson et al., 2001; Delelis et al., 2008; Knudsen et al., 2016; Maras 
et al., 2018; Mengistu et al., 2012; Pakhale et al., 2015; Quon et al., 2015; Riekert et al., 
2007) and six ‘moderate’ quality (Burge et al., 2015; Burker et al., 2004; Havermans et 
al., 2008; Hayes et al., 2011; Kopp et al., 2013; Quittner et al., 2014).   
It is important that findings of the systematic review are interpreted in light of the 
methodological strengths and weaknesses of the included studies.  Only two papers 
(Burge et al., 2015 and Quon et al., 2015) scored highly on ‘Quality of Reporting’, with 
the majority rated as ‘moderate’.   Strengths included clear reporting of aims/statistical 
analysis plan and acknowledgement of ethical approval.   Studies were penalised for not 
reporting a power calculation and minimal reporting of limitations.  In addition to these 
problems, three papers (Anderson et al., 2001; Havermans et al., 2008; and Knudsen et 
al., 2016) also had limited explanation of statistical analysis plan, and/or did not fully 
report findings, resulting in ‘low’ quality of reporting ratings.    
The majority of included studies had a participation rate exceeding 50% of all adults in 
the CF service that the research was being conducted.  However, many did not 
investigate differences between participants/non-participants.  This resulted in 
‘moderate’ ‘selection bias’ ratings as it hinders the readers’ assessment of potential 
sampling bias.   
Risk of ‘information bias’ was ‘low’ in all studies as all used valid and reliable 
measures of anxiety/depression. Although, it is important to acknowledge that these 
measures are not specific to the CF population but are used widely in services across 
Europe and USA.  
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Risk of ‘confounding bias’ was ‘moderate’ in the majority of studies.  One common 
weakness was the use of cross-sectional design which limits conclusions regarding the 
possible causal influence of factors on anxiety/depression symptoms.  Those studies that 
‘low’ ‘confounding bias’ (Delelis et al., 2008; Maras et al., 2018; Mengistu et al., 2012; 
Riekert et al., 2007) acknowledged the possibility of interactions between variables, 
accounting for this in statistical analyses.
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   Table 3. Summary of Study Quality, Risk of Bias and Overall Quality Ratings 
Paper Quality of 
Reporting 
 Risk of Bias  Overall Study Quality Rating 
Selection Information Confounding 
Anderson et al. (2001) Low Low Low Moderate High 
Burge et al. (2015) High Moderate Low Moderate Moderate 
Burker et al. (2004) Moderate Moderate Low Moderate Moderate 
Delelis et al. (2008) Moderate Moderate Low Low High 
Havermans et al. (2008) Low Moderate Low Moderate Moderate 
Hayes et al. (2011 Moderate Moderate Low Moderate Moderate 
Knudsen et al. (2016) Low Low Low Moderate High 
Kopp et al. (2013) Moderate Moderate Low Moderate Moderate 
Maras et al. (2018) Moderate Moderate Low Moderate High 
Mengistu et al. (2012) Moderate Moderate Low Low  High 
Pakhale et al. (2015) Moderate Low Low Moderate  High 
Quittner et al. (2014) Moderate Moderate Low Moderate  Moderate 
Quon et al. (2015) High Low Low Moderate  High 
Riekert et al. (2007) moderate Moderate Low Low  High 
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Demographic Factors 
Age 
Five studies examined the relationship between age and anxiety/depression symptoms 
(Anderson et al., 2001; Maras et al., 2018; Mengistu et al., 2012; Quittner et al., 2014; 
Quon et al., 2015), with the majority having a ‘high’ quality rating. One further study 
(Knudsen et al., 2016) investigated only depressive symptoms but no results were 
reported. Three studies (Anderson et al., 2001; Maras et al., 2018; Quon et al., 2015) did 
not find a significant relationship between age and either anxiety or depression 
symptoms. Mengistu et al. (2012) reported a significant positive association between 
anxiety and age, with age accounting for 2% of the variance in HADS anxiety scores.  
However, only a weak positive correlation was found between age and HADS 
depression scores, which did not contribute to the regression model. The largest study 
(Quittner et al., 2014) found that older age was significantly associated with higher 
scores on both depression and anxiety.  However, despite regression analyses being 
used, neither study reported on possible interaction effects of age with other 
demographic/health variables that may influence anxiety/depression symptoms. In both 
studies, weak effect sizes were reported therefore although results may be statistically 
significant, they may not be clinically meaningful results.   
Gender 
Six studies examined the relationship between gender and depression symptoms 
(Anderson et al., 2001; Knudsen et al., 2016; Maras et al., 2018; Mengistu et al., 2012; 
Quittner et al., 2014; Quon et al., 2015).  Four studies (Maras et al., 2018; Mengistu et 
al., 2012; Quittner et al., 2014; Quon et al., 2015) did not find a significant association, 
except Mengistu et al. (2012) which reported a weak correlation between male gender 
and depressive symptoms but this was not maintained in the regression model. 
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Significant results were reported by Anderson et al. (2001) who found a significant 
main effect of gender on depressive symptoms, with males reporting higher levels of 
depression than females. However, the mean difference between BDI scores for males 
and females was small and therefore the statistically significant difference between male 
and female depression scores may not be clinically meaningful.  Contrastingly, Knudsen 
et al. (2016) found that females were significantly more likely to report symptoms of 
depression on the MDI, with a female-male Odds Ratio of 5:1 for moderate-severe 
depression.  However, both papers had ‘moderate’ confounding bias due to possible 
interaction effects not being reported.   
With regards to anxiety, five studies examined the relationship between gender and 
anxiety symptoms (Anderson et al., 2001; Maras et al., 2018; Mengistu et al., 2012; 
Quittner et al., 2014; Quon et al., 2015). Two studies (Maras et al., 2018; Quon et al., 
2015) found no significant association and no results were reported by Mengistu et al. 
(2012). Anderson et al. (2001) reported a trend for STAI score with men reporting 
higher levels of anxiety than women.  Contrastingly, Quittner et al. (2014) reported that 
female gender was significantly associated with higher anxiety.  Again, possible 
confounding and selection biases limit these results.   Furthermore, reported effect sizes 
were small. 
Work 
Two studies (Burker et al., 2004; Quon et al., 2015) investigated the relationship 
between work status and anxiety, with both finding no significant association.  With 
regards to depression, Quon et al. (2015) found no significant results but Burker et al. 
(2004) found that those who were working had significantly lower BDI scores than 
those who were not working and this difference was clinically meaningful as the two 
groups fell into different classifications based on the BDI cut-off scores.  Furthermore, 
 25 
higher scores on BDI were significantly associated with fewer number of hours worked 
per week, but this was a small effect.  However Burker et al. (2004) paper was rated as 
‘moderate’ quality, with issues relating to selection and confounding bias, compared to 
the ‘high’ quality paper of Quon et al. (2015).  A further paper by Knudsen et al. (2016) 
did not report results of a regression model investigating effect of work status on 
depression symptoms.   
Health Factors 
Lung Functioning 
Eight studies (Anderson et al., 2001; Havermans et al., 2008; Kopp et al., 2013; Maras 
et al., 2018; Mengistu et al., 2012; Quittner et al., 2014; Quon et al., 2015; Riekert et al., 
2007) investigated the association between lung functioning (measured by FEV1% 
predicted) and depression symptoms.  Four researchers (Mengistu et al., 2012; Quittner 
et al., 2014; Quon et al., 2015; Riekert et al., 2007) found significant associations 
relating lower lung functioning to higher levels of depressive symptoms.  Mengistu et 
al. (2012) reported that lung functioning accounted for 13% of the variance in 
depression scores, whilst Riekert et al. (2007) reported that participants with poor lung 
function were three times more likely to screen positively for depression than those with 
better lung function.  These are reasonable effect sizes and the majority of these studies 
were of high quality.   
Six studies (Anderson et al., 2001; Havermans et al., 2008; Maras et al., 2018; Mengistu 
et al., 2012; Quittner et al., 2014; Quon et al., 2015) investigated the association 
between lung functioning and anxiety symptoms.  Two studies (Anderson et al., 2001; 
Quittner et al., 2014) found significant associations relating lower lung functioning with 
higher levels of anxiety symptoms.  However, reported effect sizes were small.  
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BMI 
Four studies (Anderson et al., 2001; Mengistu et al., 2012; Quittner et al., 2014; Quon et 
al., 2015) investigated the association between BMI and anxiety/depression symptoms. 
Anderson et al. (2001) used a different measurement (Ideal Body Weight) finding no 
association with depression scores, but significant association with lower STAI scores 
in those with sub-normal body weight.  For the remaining three articles, only Mengistu 
et al. (2012) found a significant association between BMI and depression, accounting 
for 8% of the variance in depression scores. With regards to anxiety, only Quittner et al. 
(2014) reported significant results, with lower BMI being significantly associated with 
anxiety. However, there were concerns regarding selection and confounding bias in this 
paper and the reported odds ratio was close to the null.  
Pain 
Two studies (Hayes et al., 2011; Maras et al., 2018) investigated the relationship 
between pain presence and anxiety/depression symptoms. Both reported significant 
positive associations but reported effect sizes were small.  Furthermore, there was 
possible selection bias in both papers and confounding bias in Hayes et al. (2011).   
Other Health Factors     
Quittner et al. (2014) investigated the association between several health factors and 
anxiety/depression symptoms.  Significant positive associations were found between 
anxiety/depression scores and having a haemoptysis/pneumothorax in the past six 
months, recent intravenous antibiotics and listed for transplant but all with small effect 
sizes.  Further significant positive associations were found between anxiety/depression 
and taking psychiatric medications/receiving psychotherapy, both with higher effect 
sizes. However, no confounding variables or interaction effects between variables were 
considered resulting in a ‘moderate’ quality rating.    
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Psycho-Social Factors 
Health-Related Quality of Life 
Six studies (Havermans et al., 2008; Knudsen et al., 2016; Kopp et al., 2013; Maras et 
al., 2018; Mengistu et al., 2012; Riekert et al., 2007) investigated the relationship 
between HRQoL and depression symptoms.  All studies, except Kopp et al. (2013), 
found significant associations, with poor HRQoL being associated with more depressive 
symptoms.  The majority of these papers were ‘high’ quality, with medium to large 
effect sizes reported.  Mengistu et al. (2012) found that HRQoL accounted for 23% of 
the variance in depressive symptoms.  Riekert et al. (2007) reported that the association 
between depressive symptoms and HRQoL scales was maintained regardless of lung 
functioning. This was replicated by Havermans et al. (2008) who reported that after 
controlling for lung function those with depressive symptoms reported significantly 
lower HRQoL scores for emotional functioning, eating disturbance and body image.  
With regards to anxiety, three studies (Havermans et al., 2008; Maras et al., 2018; 
Mengistu et al., 2012) found a significant association, with poorer HRQoL being 
associated with higher levels of anxiety symptoms.  Reported effect sizes ranged from 
small to large across studies.  Specifically, Havermans et al. (2008) reported that after 
controlling for lung function, those patients who reported symptoms of anxiety had 
significantly poorer HRQoL scores on a variety of domains.  Furthermore, Mengistu et 
al. (2012) found that interpersonal relationships domain accounted for 15% of variance 
and chest symptoms domain accounted for 9% of variance in anxiety scores. 
Anxiety/Depression 
Three studies (Delelis et al., 2008, Maras et al., 2018; Quittner et al., 2014) investigated 
the association between anxiety and depression symptoms themselves, with all studies 
finding significant positive associations with large effect sizes.  Quittner et al. (2014) 
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found that adults reporting anxiety were 13.64 times more likely to report elevated 
depression than those not elevated on anxiety.   
Relationship Status 
Two studies (Knudsen et al., 2016; Quon et al., 2015) investigated the association 
between relationship status (defined as either single or with partner/married) and 
anxiety/depression symptoms.  No significant association was found by Quon et al. 
(2015) and no data was reported by Knudsen et al. (2016). Interaction effects were not 
explored or discussed by either study.  
DISCUSSION 
To the author’s knowledge this is the first systematic review that has examined and 
synthesised factors associated with anxiety/depression in adults with CF. This review 
established nine demographic, health or psycho-social factors that had been investigated 
by at least two studies.  A further five health factors investigated by only one study 
(Quittner et al., 2014) were retrospectively deemed important to include due to the 
substantial international sample population.  Of the principal nine factors, 
anxiety/depression symptoms were consistently associated with each other and with 
HRQoL.  Large effect sizes were reported from high quality papers, suggesting 
confidence in the results and demonstrating the clinical relevance of the findings.  
Further consistent positive associations were found between anxiety/depression 
symptoms and pain in studies that were of reasonable quality.  Effect sizes were, 
however, small and the differences in anxiety/depression symptom scores between 
‘pain’ and ‘no pain’ group were not considered to be clinically significant.   
Relationship status was not associated with anxiety/depression.  The remaining five 
factors (age, gender, work status, lung functioning, BMI) had variable results across 
studies with some finding significant associations with anxiety/depression symptoms 
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and others finding no associations. Again there was variability in reported effect sizes 
and therefore some statistically significant results were not deemed clinically relevant.  
The five additional health factors (haemoptysis/pneumothorax, intravenous antibiotics, 
transplant, psychiatric medications and psychotherapy) that Quittner et al. (2014) 
identified were all significantly positively associated with anxiety/depression.   
However, only the latter two factors had clinically meaningful differences in 
anxiety/depression symptoms between the groups.   
There are many possible reasons why results varied across studies.  Firstly, it is 
important to consider study quality ratings when interpreting and synthesising results. 
Selection bias issues were frequent due to papers not exploring/reporting differences 
between participants/non-participants.  Furthermore, the majority of studies did not 
account for confounding variables or investigate potential interaction effects between 
health, physical or psycho-social factors.  It is possible that individually the factors may 
not be associated with anxiety/depression symptoms, but collectively they are.   These 
are methodological issues that should be addressed in future studies before final 
conclusions can be made.  Next, sample size varied greatly across studies and power 
calculations were omitted in the majority.  Some studies reported trends in associations 
between factors and anxiety/depression symptoms which suggested that a significant 
association may be present but the study was under-powered.    Furthermore, studies 
had very low numbers of participants presenting with depression/anxiety symptoms 
above the relevant clinical cut-off point. Although this may be representative of the 
general CF population, for research purposes it may be beneficial to have a greater 
spread of anxiety/depression symptom levels to detect factors associated with higher 
levels of depression/anxiety.  A further consideration is that the cross-sectional nature of 
all studies prevented causality being determined as it is only possible to conclude that 
there is an association rather than a causal relationship. Longitudinal designs are better 
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placed to identify predictors of anxiety/depression.  A final issue regarding the 
variability of results is the variety of measurement tools used which prevents direct 
comparison across studies.  As none of the generic screening tools have been 
definitively validated in a CF population, it is recognised that current tools may not 
adequately detect CF-related psychosocial difficulties (Oxley & Webb., 2005).     
Implications for future research 
It is acknowledged that the prevalence and impact of anxiety/depression in adult CF 
populations is a relatively new area of interest, with only one major international study 
being conducted so far.  While the studies in this review were early stage explorations, 
the results indicate the value in continuing with this research. Longitudinal designs 
would allow for causality to be investigated and take into account possible interaction 
effects between variables. Larger sample sizes, gained by international collaboration, 
would promote adequate power to detect significant results.  Finally, the development 
of a CF-specific measure of anxiety/depression would ensure a consistent approach to 
both research and clinical practice.     
Limitations 
This systematic review had several limitations.  First the exclusion of unpublished 
studies may have introduced publication bias as three relevant papers were excluded due 
to being university dissertations.  However, the peer-reviewed criteria acted as a filter 
offering some reassurance about the quality of included articles.  Furthermore, the initial 
decision to only report on factors that had been investigated by two papers may have 
introduced a selection bias, overlooking important factors that may be associated with 
anxiety/depression symptoms.  However this criterion was incorporated so as to not 
make conclusions based on single study findings which could potentially be unreliable.  
A further limitation is that this review focused exclusively on anxiety/depression but as 
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discussed previously there are reservations about whether this accurately covers all the 
distress experienced by adults with CF. The inclusion of a wider range of mental health 
difficulties may have added to a broader understanding of the distress experienced in 
CF.  Other limitations that have been acknowledged relate to the methodological 
weaknesses of the included studies such as the exclusive use of cross-sectional designs, 
limited investigation of interaction effects between factors and potential lack of power.  
Finally, the search, screening and extraction were done by one person, potentially 
raising the risk of bias. 
CONCLUSION 
Awareness of factors that may be associated with anxiety/depression can aid the 
identification of ‘at-risk’ individuals and encourage appropriate support to be provided. 
This review found both consistent and inconsistent associations between 
anxiety/depression symptoms and a variety of demographic, health and psycho-social 
factors in an adult CF population.  The papers were of reasonable quality providing a 
sound basis for this research, but the variability in results prevents definitive 
conclusions from being drawn at this stage.  Furthermore, the reported effect sizes of 
statistically significant results were frequently small, therefore raising the question of 
the clinical meaningfulness of the results.  Future research should (1) use large scale 
longitudinal studies to determine causality and explore interaction effects, (2) seek to 
replicate findings of single studies, and (3) consider the development of a CF specific 
measure of anxiety/depression.    
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PLAIN ENGLISH SUMMARY 
Background 
Adults with Cystic Fibrosis (CF) are at a higher risk of experiencing anxiety and 
depression than the general population.  It is important that psychological distress is 
recognised as if left untreated it can lead to poor health-related quality of life, poor 
treatment adherence, poor health outcomes and increased healthcare costs.  There are 
concerns that the current questionnaires used in CF services are not the best tools to 
detect the distress that individuals with CF experience.  The Distress in Cystic Fibrosis 
Scale (DCFS) was developed to meet this need.   
Aims  
This study aimed to explore the DCFS tool in order to support its development as an 
appropriate measure of distress for adults with CF.    
Methods  
119 participants were recruited from the West of Scotland Adult Cystic Fibrosis Service 
(WoSACFS) either through out-patient clinic appointments or in-patient wards.  After 
providing consent, participants completed four different questionnaires looking at their 
mood, quality of life and current levels of distress.  Current physical health 
measurements were also recorded and participants were given the opportunity to give 
feedback on the questionnaires.  The data was then explored and analysed.   
Results  
The results suggested that the DCFS is able to detect current difficulties that adults with 
CF experience, and is able to distinguish between those who are experiencing high 
levels of distress and those who are experiencing low levels of distress.  Additionally, 
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positive feedback was provided by participants about the DCFS in comparison to 
existing tools.  Further exploratory analyses highlighted improvements that could be 
made to the instructions and response scale to ensure that individuals were rating both 
current and potential future distress relating to all items.   
Conclusions 
The current study provides initial support for the DCFS being used as a measure of 
distress in an adult CF population.  Suggestions were made to improve the wording of 
the instructions and response scale used in the DCFS.  Studies in the future should 
continue to investigate the revised version of the DCFS using a larger sample.    
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ABSTRACT 
Background 
Anxiety and depression are highly prevalent in adults with Cystic Fibrosis (CF) and can 
lead to numerous negative outcomes including poorer physical health and health related 
quality of life, reduced treatment adherence and increased healthcare costs.  Currently it 
is recommended that all adults with CF are screened for anxiety and depression on an 
annual basis.  However, there are concerns that these current measures do not 
adequately detect the range of difficulties that individuals with CF experience.  
Consequently, the Distress in Cystic Fibrosis Scale (DCFS) was developed to support 
the detection of distress specifically in an adult CF population.  This study was an initial 
exploration of the structural and psychometric properties of the DCFS in order to 
support its development as an appropriate screening measure of distress in an adult CF 
population.   
Methods 
119 participants were recruited from the West of Scotland Adult Cystic Fibrosis Service 
(WoSACFS) through inpatient wards and out-patient clinics.  Participants completed a 
battery of questionnaires assessing their mood, quality of life and current distress 
relating to CF. Psychometric properties of the DCFS were then evaluated with 
additional exploratory analyses evaluating the structure and practical use of the 
measure.  
Results 
The results indicated a 1-component model for the DCFS and provided support for it 
being an appropriate measure of CF distress, with positive findings relating to internal 
consistency and criterion validity. However, exploratory analyses highlighted that two 
response categories (N/A and 0) were used inconsistently by participants particularly for 
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those items concerning physical health symptoms. It is possible that this was due to the 
wording of the rating scale and instructions.    
Conclusions 
The current study provides preliminary support for the DCFS being used as a measure 
of distress in an adult CF population.  Potential improvements to the instructions and 
response scale were identified and subsequent recommendations made.  Future studies 
should be conducted to further investigate the psychometric properties of the revised 
tool using a larger sample with a greater range of clinical and demographic 
characteristics.   
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INTRODUCTION 
Cystic Fibrosis (CF) is an inherited, progressive and life-limiting condition in which the 
lungs and digestive system can become obstructed by thick, sticky mucus.  Despite 
recent advances in diagnosis and treatment, management of CF requires a complex, 
time-consuming daily regime taking two to four hours, in addition to over 20 
medication tablets a day. Despite this demanding treatment routine, individuals with CF 
may experience frequent infections and progressive failure of most organ systems (e.g. 
lungs, pancreas). 
Research (Smith and Schmitz, 2014; Yang et al., 2013) has shown that adults with 
chronic conditions, such as cancer and diabetes, are at higher risk of experiencing 
depression and anxiety compared to community samples without chronic health 
conditions. Quittner et al. (2014) conducted an extensive study of 6088 patients with CF 
(The International Depression Epidemiological Study -TIDES) and found that 
depression and anxiety rates were 2-3 times higher in individuals with CF than those 
without CF.  Research has shown that prolonged psychological distress, particularly 
depressive symptoms in patients with CF, is associated with poor Health-Related 
Quality of Life (HRQoL) and poor health outcomes (Riekert et al., 2007); increased 
healthcare utilisation and costs (Snell et al., 2014); and poor treatment adherence 
(Knudsen et al., 2016).   Given these relationships between psychological distress and 
key health/quality of life outcomes it is important that screening measures accurately 
detect psychological distress in individuals with CF.   
Due to financial and time constraints it is not possible to offer everyone with CF an 
annual clinical psychology interview and therefore screening measures are routinely 
used to detect psychological distress.  The International Committee on Mental Health in 
Cystic Fibrosis (ICMH-CF) (Quittner et al., 2016) advises using the Patient Health 
Questionnaire (PHQ-9) and Generalised Anxiety Disorder Questionnaire (GAD-7). 
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However, historical research (Oxley &Webb., 2005) and current professionals working 
in CF services have raised concerns that these generic screens may not adequately 
detect psychosocial difficulties in a CF population as clinically ‘normal’ scores may be 
achieved by patients with CF for whom clinical assessment reveals psychosocial 
difficulties. 
Disease-specific measures of distress exist in other long-term conditions such as the 
Diabetes Distress Scale (DDS) (Polonsky et al., 2005) and the Distress Thermometer 
(DT) for cancer services (Hoffman et al., 2004).  These measures were developed due to 
individuals experiencing distress related to their physical health condition.  It is 
important to highlight that the term ‘distress’ is used as this is a non-stigmatizing term 
that describes the broad array of difficulties that individuals with physical health 
conditions can experience (Holland, 1997). In relation to CF, Pakhale et al. (2015) 
found that in addition to general mood and anxiety difficulties, adults were interested in 
discussing several other issues with a psychologist.  These included CF-specific 
adjustment difficulties, treatment adherence, quality of life concerns, death and 
difficulties with stigma/disclosure to others.   Therefore, the aim of these distress 
measures is not to identify psychopathology, but to identify areas where further 
assessment and intervention may be beneficial, ranging from physical problems to 
practical concerns about their CF condition.   
As far as the authors are aware there are no current validated measures of distress in an 
adult CF population.  One of the present study’s authors, Dr Sejal Patel, began 
developing a measure of distress for an adult CF population and the Distress in Cystic 
Fibrosis Scale (Patel, 2015) was created.  Over a three-year period, 150 adult patient 
files were audited to ascertain the emotional concerns CF patients presented with to the 
clinical psychologist in an adult CF service.  Thirty themes of psychosocial concerns 
were identified of which eight were excluded due to being isolated occurrences (e.g. 
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domestic violence and perceptual disturbance). The remaining 22 themes were included 
in the developed questionnaire which was constructed by adapting the framework of 
previously validated measures of distress in long-term conditions. For example, the 0-10 
rating scale used in the DT (Hoffman et al., 2004) and the wording of instructions in the 
DDS (Polonsky et al., 2005).  It was presented to clinical psychology CF outpatients 
during face-to-face contact, and was sent to the CF Multidisciplinary Team to check 
face validity, with positive feedback received. In 2015 the questionnaire was shown to 
the UK Psychosocial Professions in CF Group (UKPP-CF) where suggestions for 
format improvement were made and one further item added.   
The final 23-item questionnaire is intended to be a quick, self-report measure that CF 
patients can complete to highlight the areas in which they are currently experiencing 
distress and to allow for further assessment and appropriate support to be provided.  
Formal exploration of the psychometric properties of the DCFS is required before it can 
be disseminated and used in clinical practice.    
AIMS 
This project is the first phase to evaluate the structure and psychometric properties of 
the DCFS, a newly-developed self-report measure of distress in an adult CF population. 
Principal Component Analysis (PCA), internal consistency, criterion validity and 
content validity were investigated, in addition to reviewing participants’ written 
feedback regarding the DCFS.  This is the first structured exploration of the DCFS and 
the results will inform recommendations about the future use of the DCFS and any 
further investigations that should be conducted.     
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METHODS 
Ethical approval 
A research protocol was developed (Appendix 4, p.72) with initial and subsequent 
amendments to the study protocol being granted ethical approval by West of Scotland 
Rec Four committee and by NHS Greater Glasgow and Clyde R&D (Appendix 5, p.84). 
Sample size 
There is limited literature guidance on sample size required for validation studies.  A 
review by Anthoine et al. (2014) reported that the sample size determination for 
psychometric validation studies (using exploratory factor analysis and common 
validity/reliability analyses) is rarely ever justified a priori. They found that 
approximately 92% of the articles reported a subject-to-item ratio greater than or equal 
to two, with about 90% of articles having a sample size greater than or equal to 100.  
The current DCFS tool has 23 items therefore, taking into account the review findings 
and the scope of the current research project, a subject-to-variable ratio of 5/1 was 
chosen. Thus, the current study aimed to recruit 115 participants. 
Participants 
119 participants were recruited from the West of Scotland Adult Cystic Fibrosis Service 
(WoSACFS).  Eligible participants were those who had a diagnosis of CF, aged 18 or 
over, and fluent in English.  Individuals who had a learning disability or who were 
deemed too physically unwell to participate were excluded from the study.  One 
hundred and thirty seven individuals were invited to participate, with 11 declining and 
seven not returning questionnaires by post.  Overall there was an 87% participation rate.    
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Measures  
Physical Health information – Recent Body Mass Index (BMI) and lung functioning 
(using FEV1%) measurements were recorded from participants’ medical files if consent 
was provided.   
Distress in Cystic Fibrosis Scale (DCFS; Patel, 2015) is a 23-item questionnaire 
(Appendix 6, p.92).  It has an 11-point range with endpoints labelled ‘no problems’ (0) 
and ‘worst I’ve ever felt’ (10).  Respondents are instructed to write the number (0-10) 
that best describes how they have been feeling over the past two weeks relating to each 
of the 23 items.  Some items are not relevant to everyone therefore all ‘N/A’ responses 
were coded as such in SPSS so as to differentiate from genuine missing data.  
Furthermore, a mean score was calculated for the purpose of some analyses by 
summing the distress ratings provided, then dividing this by the number of items 
answered by the participant.   
Patient Health Questionnaire-8 (PHQ-8; Kroenke et al., 2009) is an eight-item self-
report measure of depression, using a four-point scale from ‘not at all’ to ‘nearly every 
day’.  Responses are based on how the individual has been feeling over the past two 
weeks.  Evidence supports reliability and validity of PHQ-8 as a measure of depression 
in the general population (Kroenke et al., 2009).  
Generalised Anxiety Disorder Questionnaire-7 (GAD-7; Spitzer et al., 2006) is a seven-
item self-reported questionnaire, using a four-point scale from ‘not at all’ to ‘nearly 
every day’.  Responses are based on how the individual has been feeling over the past 
two weeks. Evidence supports reliability and validity of the GAD-7 as a measure of 
anxiety in the general population (Lowe et al., 2008).  
Cystic Fibrosis Questionnaire – Revised (CFQ-R; Quittner et al., 2000) is a 50-item 
disease-specific health-related quality of life (HRQOL) measure for adults with CF.  
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There are nine HRQOL domains; three symptom scales and one overall health 
perception scale.  The CFQ-R demonstrated robust psychometric properties and 
consistent associations with health outcomes in a large national sample (Quittner et al., 
2012).  
Evaluation Form – Participants were asked to rate how much each questionnaire 
covered their current difficulties using a four-point scale from ‘did not cover any of my 
difficulties’ to ‘covered all of my difficulties’.   Participants also rated how easy or 
difficult each questionnaire was to complete using a five-point scale from ‘very 
difficult’ to ‘very easy’ (Appendix 7, p.93).    
Procedure 
Potential participants were informed about the research by a familiar clinician either at 
their multi-disciplinary clinic appointment or during their in-patient stay.  If interested 
they were provided with a research pack including a participant information sheet 
(Appendix 8, p.95) and consent form (Appendix 9, p.99).  Participants were able to 
complete the research pack during their visit or post it back using a pre-paid envelope.  
Data analysis  
Principal Component Analysis - to explore the structure of DCFS; to identify whether 
there was any evidence of the questionnaire measuring different components; to 
highlight redundant/unrelated items.   
Internal Consistency - refers to how well the items on the DCFS relate to each other.  It 
was tested using Cronbach’s Alpha.  An alpha score of >.9 indicates ‘excellent’ internal 
consistency and an alpha of 0.8-0.9 indicates ‘good’ internal consistency (George & 
Mallery, 2003).    
Criterion Validity - investigated by exploring the extent to which DCFS scores 
correlated with other validated measures, with additional descriptive analyses exploring 
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this relationship.  A correlation coefficient of +/-.3 represents a medium effect and +/-.5 
represents a large effect (Field, 2013).  It was also investigated by the ability of the 
DCFS to discriminate between those experiencing psychological distress and those who 
are not. A Mann Whitney test compared DCFS scores between participants who scored 
ten and above, and participants who scored below ten (clinical cut-off point) on GAD-
7/PHQ-8. 
Content Validity - is the degree to which items are representative and relate to the 
construct being measured (Haynes et al., 1995).  It is determined via expert judgement.  
During the analyses, the researcher noticed possible inconsistencies regarding 
participants’ use of the response scale. Consequently, further exploratory/descriptive 
statistics were conducted to investigate the practical usage of the DCFS and the wording 
of the instructions and response scale.    
Participant’s feedback - descriptive statistics were used to evaluate participants’ ratings 
of the questionnaires.   
Missing data was coded as such in SPSS and all analyses were run with pairwise 
deletion where possible so as to maximise sample size and power.   
RESULTS 
Participant demographics 
Table 1 provides a summary of participant characteristics.  The data are skewed towards 
Caucasian, out-patient and ‘non-cepacia’ (classification of bacteria growth in CF) 
categories. Mean age of participants was 30.7 years.  There was a relatively 
representative spread across other categories of marital status, education and work 
status.  
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Table 1. Summary of participant demographics and clinical characteristics 
Age: Mean (SD)  30.7 (11.1) 
Gender: n (%) Male 68 (57.1) 
Female 51 (42.9) 
Marital Status: n 
(%) 
 
Single 49 (41.2) 
Married 27 (22.7) 
Divorced 2 (1.7) 
Separated 1 (.8) 
With a partner 39 (32.8) 
Missing data 1 (.8) 
Education: n (%) Secondary school or less 25 (21) 
GCSEs level (or equivalent) 15 (12.6) 
A/AS level (or equivalent) 10 (8.4) 
Other higher education 30 (25.2) 
University degree 24 (20.2) 
Professional qualification or post-graduate study 14 (11.8) 
Missing data 1 (.8) 
Race: n (%) White – UK 112 (94.1) 
White – other 3 (2.5) 
Indian/Pakistani 2 (1.7) 
Other 1 (.8) 
Missing data 1 (.8) 
Current Work 
Status: n (%) 
Attending school outside of home 8 (6.7) 
Taking education courses at home 1 (.8) 
Seeking work 6 (5) 
Working full or part time 68 (57.1) 
Full time homemaker 1 (.8) 
Not attending school or work due to health 23 (19.3) 
Not working for other reasons 10 (8.4) 
Missing data 2 (1.7) 
Pathogen growth: n 
(%) 
  
Non cepacia 99 (83.2) 
Cepacia 12 (10.1) 
Abscessus 8 (6.7) 
Setting: n (%) Outpatient 92 (77.3) 
Inpatient 27 (22.7) 
Clinical Measures: 
mean, SD 
Personal Health Questionnaire Depression Scale (PHQ-
8) – total score 
5.4 (5.1) 
Generalised Anxiety Disorder Questionnaire (GAD-7) 
– total score 
4.6 (4.5) 
Distress in Cystic Fibrosis Scale (DCFS) – mean score 19.6 (16.3) 
Cystic Fibrosis Questionnaire-Revised (CFQ-R) –        
(range across twelve domains) 
51.4-84.7 
(18.3-37.3) 
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Principal Component Analysis  
A Principal Component Analysis (PCA) was run on the 23-item DCFS.  The suitability 
of PCA was assessed prior to analysis.  Inspection of the correlation matrix showed that 
all variables had at least one correlation coefficient greater than 0.3.  The overall Kaiser-
Meye-Olkin (KMO) measure was 0.83, with individual KMO measures all greater than 
0.6.  Bartlett’s test of sphericity was statistically significant (p<0.001), indicating that 
the data was likely factorisable. PCA revealed five components that had eigenvalues 
greater than one and which explained 37.3%, 7.5%, 7.4%, 6.1%, and 5.3% of the total 
variance, respectively.  The five-component solution explained 63.7% of the total 
variance but after applying Direct Oblimin rotation the rotated solution did not exhibit a 
simple or meaningful structure (see Table 2). Subsequent exploratory PCA’s were 
conducted, with the two and four component solutions exhibiting the most simple 
structure, but meaningful interpretation continued to be difficult.  On further inspection 
of the extraction criteria, the first component had an Eigen value of 8.6, with the 
remaining four components having Eigen values between 1-1.7.  Additionally, the scree 
plot clearly demonstrated one component before the inflection point. Consequently, a 
one component solution was extracted, with all items loading strongly, providing 
support to retain all items (see Table 3).  Finally, this one component solution could be 
meaningfully interpreted as measuring the construct ‘distress’.   
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Table 2. Pattern and Structure Matrix for 5-component solution 
PATTERN MATRIX 
DCFS Item Component 
1 2 3 4 5 
DCFS_22 .785 .031 -.061 .073 -.011 
DCFS_2 .721 .162 .172 -.137 .118 
DCFS_16 .664 -.173 .137 -.020 .061 
DCFS_23 .623 -.034 .005 .328 .065 
DCFS_1 .480 .328 .001 -.189 .307 
DCFS_10 -.138 .700 .101 -.228 .276 
DCFS_21 -.206 .674 .207 .307 -.214 
DCFS_9 .394 .661 -.053 .042 -.165 
DCFS_8 .217 .571 -.279 .075 .275 
DCFS_7 .390 .403 .307 .264 -.015 
DCFS_6 .311 .352 .221 .269 .062 
DCFS_4 .193 .209 .675 .140 -.067 
DCFS_5 .307 -.152 .662 .123 .240 
DCFS_3 -.098 .123 .603 -.103 .502 
DCFS_20 -.153 .078 .276 .738 .003 
DCFS_17 .002 -.005 -.023 .668 .242 
DCFS_19 .219 -.066 -.085 .628 -.039 
DCFS_13 .040 .232 -.397 .460 .419 
DCFS_11 .088 -.016 .130 -.086 .739 
DCFS_15 .126 -.121 .086 .211 .723 
DCFS_12 .008 .151 .001 .364 .492 
DCFS_18 .254 .029 .012 .237 .490 
DCFS_14 .399 .236 -.124 .193 .419 
 
STRUCTURE MATRIX 
DCFS Item Component 
1 2 3 4 5 
DCFS_22 .801 .212 .048 .303 .315 
DCFS_2 .785 .346 .295 .151 .440 
DCFS_23 .750 .209 .120 .523 .406 
DCFS_16 .660 .007 .201 .157 .298 
DCFS_14 .658 .455 .043 .447 .658 
DCFS_1 .621 .466 .145 .097 .537 
DCFS_9 .482 .711 .079 .275 .155 
DCFS_10 .075 .699 .217 -.033 .359 
DCFS_21 -.024 .681 .279 .379 -.032 
DCFS_8 .441 .661 -.114 .312 .476 
DCFS_7 .590 .598 .438 .496 .343 
DCFS_6 .522 .536 .347 .476 .365 
DCFS_4 .340 .376 .734 .287 .194 
DCFS_5 .488 .109 .723 .283 .451 
DCFS_3 .175 .294 .677 .056 .562 
DCFS_20 .116 .264 .329 .735 .164 
DCFS_17 .289 .211 .067 .718 .384 
DCFS_19 .361 .110 -.023 .661 .156 
DCFS_13 .342 .391 -.255 .586 .532 
DCFS_15 .458 .148 .210 .383 .802 
DCFS_11 .369 .185 .243 .107 .771 
DCFS_18 .525 .265 .142 .425 .651 
DCFS_12 .344 .361 .130 .510 .612 
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Table 3. One-component solution 
DCFS Item Component 1 
 
DCFS_1 .662 
DCFS_2 .704 
DCFS_3 .500 
DCFS_4 .538 
DCFS_5 .618 
DCFS_6 .720 
DCFS_7 .781 
DCFS_8 .638 
DCFS_9 .572 
DCFS_10 .395 
DCFS_11 .575 
DCFS_12 .657 
DCFS_13 .595 
DCFS_14 .808 
DCFS_15 .692 
DCFS_16 .484 
DCFS_17 .556 
DCFS_18 .701 
DCFS_19 .442 
DCFS_20 .462 
DCFS_21 .334 
DCFS_22 .621 
DCFS_23 .718 
 
 
Internal Consistency 
The 23-item DCFS was found to have high internal consistency (α=.913 n=65), with a 
range for the total scale, as measured by alpha if item-deleted, between 0.905- 0.914.  
However, in this analysis ‘N/A’ responses were considered to be missing data resulting 
in the analysis using only 50% of the study population.  To overcome this, ‘N/A’ 
responses were re-coded as ‘0’ (given that N/A does mean that there was no distress 
relating to that item) and the analysis rerun.  High internal consistency (α=.911 n=119) 
was again demonstrated, with a range for the total scale, as measured by alpha if item-
deleted, between 0.902- 0.912. 
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Criterion Validity 
Based on theoretical and empirical considerations, a series of associations between 
DCFS items and previously validated measures were chosen a priori. A Spearman 
correlation analysis was used due to data being ordinal and not all variables being 
normally distributed, as assessed by Shapiro-Wilk test (p< .05).  Table 4 illustrates that 
all correlations were in the predicted direction, and all met statistical significance 
criteria (p<.05), supporting DCFS criterion validity.   
Table 4. Summary of a priori chosen correlations 
 DCFS Q1* DCFS Q2 DCFS Q7 DCFS Q9 
FEV 1 
Rho = -.26, p=.007 
N=107 
   
PHQ-8 
Total 
 
Rho = .73, p<.001 
N=118 
  
GAD-7 
Total 
 
Rho = .74,p<.001 
N=119 
  
CFQ-R 
Physical  
Rho = -.66,p<.001 
N=118 
   
CFQ-R 
Emotion  
 
Rho= -.76, p<.001 
N=118 
  
CFQ-R 
Social  
  Rho = -.47, p<.001, 
N=118 
 
CFQ-R 
Eating  
   Rho= -.57, p<.001, 
N=118 
Key: CFQ-R = Cystic Fibrosis Questionnaire-Revised; DCFS = Distress is Cystic Fibrosis Scale; 
FEV1 = Forced Expiratory Volume; GAD-7 = Generalised Anxiety Disorder Questionnaire; PHQ-8= 
Personal Health Questionnaire Depression Scale 
*DCFS Q1 = How have you been feeling physically? 
  DCFS Q2 = How have you been feeling emotionally? 
  DCFS Q7 = How have you been feeling about your relationships with other people? 
  DCFS Q9 = How have you been feeling about your body, weight and/or eating? 
 
Large effects were found between DCFS Q2 and already validated measures, with 
Figure 1 illustrating scatterplots of these significant positive correlations.  However, it 
also highlights the variation with some participants scoring low (below 10) on PHQ-
8/GAD-7 and high (above 5) on DCFS Q2, and vice versa of scoring high on the PHQ-
9/GAD-7 but low on the DCFS item 2. 
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Figure 1. Scatterplots of DCFS Q2 
 
 
 
 
 
 
 
 
 
 
 
The data were then split into those who scored seven or above on at least one item on 
the DCFS and those who did not.  A cut-off score of seven was selected to ensure that 
the group represented those who rated themselves as experiencing levels of distress at 
the higher end of the scale. Differences between the groups on PHQ-8 and GAD-7 total 
scores were investigated and boxplots presented in Figure 2.  As expected, participants 
who had scored seven or above in at least one item on DCFS had higher PHQ-8 and 
GAD-7 scores than those who scored below seven on all items.  However, the mean 
PHQ-8 and GAD-7 scores for the group who had scored seven or more on one item 
were 8.8 and 7.4 respectively which did not meet clinical cut-off point of 10.   Overall 
these analyses suggest that the DCFS is able to pick up difficulties detected by the 
 54 
PHQ-8 and GAD-7, but it is also able to detect additional distress that is not identified 
by the PHQ-8 or GAD-7.   
Figure 2. Boxplots of PHQ-8 and GAD-7 total scores   
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Next, the ability of the DCFS to discriminate between those scoring above and below 
clinical cut-off point (10) on PHQ-8 and GAD-7 was evaluated (see Figure 3 for 
boxplots). Distributions of the DCFS mean score for ‘depressed’ and ‘non-depressed’ 
groups were not similar, as assessed by visual inspection.  A Mann Whitney test 
revealed DCFS total scores for ‘depressed’ group (mean rank = 95.81) were 
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significantly higher than for ‘non-depressed’ group (mean rank = 49.49), U = 275, z=-
6.12, p<.001, ɳ2 = 0.32.  
Similar results were found when comparing ‘anxious’ and ‘non-anxious’ groups, with 
distributions of the DCFS total score for each group not being similar, as assessed by 
visual inspection.  A Mann Whitney test revealed DCFS total scores for ‘anxious’ group 
(mean rank = 95.75) were significantly higher than for ‘non-anxious’ group (mean rank 
= 51.89), U = 280.5, z=-5.39, p<.001, ɳ2 = 0.25.  Therefore, the DCFS is able to 
discriminate between those scoring above and below the clinical cut-off for GAD-7 and 
PHQ-8.   
Figure 3. Boxplots of DCFS Mean Score 
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Content Validity 
The method used to create the DCFS supports content validity of the screening tool. 
Visual inspection of boxplots (see Figure 4) revealed responses were skewed towards 
the lower end of the distress scale, with medians for all items being under three.  For 
four items (13, 15, 17, 21) only outliers were presented as up to 80% of participants 
responded ‘0’ or ‘N/A’.  However, for every item, including those with only outliers, 
the boxplots illustrate a range of distress ratings provided by participants from ‘0’ to at 
least ‘8’, with the majority of items having scores of ‘10’ by several participants.  These 
descriptive analyses provide support for the ‘0-10’ scale and for all items to be included 
in the DCFS. 
 
Figure 4. Boxplots for all DCFS items 
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Further exploratory analyses were conducted to investigate the distribution of responses 
across all items (Appendix 10 p.100) and to consider the wording of the response scale. 
For items relating to specific physical health symptoms (11, 13, 15, 17), there was a 
high percentage (60-70%) of participants rating these as ‘0’.  Due to the wording of ‘no 
problems’ being associated with the score of ‘0’ on the visual scale at the top of the 
questionnaire it is unclear whether participants were reporting ‘no distress’ in that area 
as intended, or whether they meant that the specific item did not apply to them.  
Furthermore, Q22 regarding ‘upsetting past events’ was only recorded by one 
participant as ‘N/A’, whilst 73 (61.3%) recorded it as ‘0’.  It would be unlikely that 
these individuals have all experienced significant previous upsetting events and do not 
have any current distress in that area.  It is more likely that they are using the rating ‘0’ 
to indicate that the item does not apply to them.  Overall these data suggest that 
participants are possibly interchanging between ‘N/A’ and ‘0’ responses, particularly on 
certain physical health items.      
Questionnaire evaluation 
Tables 5 and 6 illustrate participants’ evaluation of the questionnaires, with participants 
consistently rating the DCFS as better than the PHQ-8 and GAD-7 in relation to how 
well it covered their difficulties.  With regards to ease of completion, all questionnaires 
were rated the same. This demonstrates that the DCFS is deemed to be comparable, if 
not better than currently used measures.  Of the 32 participants who provided written 
feedback, at least 50% commented on the usefulness of the questionnaires, with specific 
positive feedback on the DCFS: 
‘CFQ-R is very long-winded and at times hard to follow.  DCFS – is the best of 
the measures. Questions are specific and cover all areas of CF but not so long 
that you get tired and lose interest.  The 1-10 scoring system is also better as it 
allows more precise and nuanced answers then the other scoring systems.’ 
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‘I feel the questionnaire covered all aspects of living daily life with CF…. the 
questionnaire also gives you the opportunity to express any negative feelings 
you have regarding your CF’ 
The most common criticism of the questionnaires was in relation to the rating scales 
with participants providing mixed opinions about which rating scale was the most 
helpful.  The inclusion of comment boxes was a repeated suggestion by participants as 
would allow them to expand on their responses.     
Table 5. N (%) responses to how well questionnaires covered current difficulties 
 Did not cover 
any of my 
difficulties 
Covered some of 
my difficulties 
Covered most of 
my difficulties 
Covered all of 
my difficulties 
DCFS 3 (2%) 18 (15%) 44 (37%) 45 (37%) 
PHQ-8 3 (2%) 30 (25%) 41 (34%) 36 (30%) 
GAD-7 9 (7%) 28 (23%) 34 (28%) 39 (32%) 
CFQ-R 3 (2%) 20 (16%) 36 (30%) 51 (42%) 
Key: CFQ-R = Cystic Fibrosis Questionnaire-Revised; DCFS = Distress in Cystic Fibrosis Scale; 
GAD-7 = Generalised Anxiety Disorder Questionnaire; PHQ-8 = Personal Health Questionnaire 
Depression Scale 
 
Table 6. N (%) responses to how easy or hard questionnaires were to complete 
 Very Difficult Difficult OK Easy Very Easy 
DCFS 0 1 (<1%) 18 (15%) 25 (21%) 59 (49%) 
PHQ-8 1 (<1%) 2 (1%) 15 (12%) 24 (20%) 61 (51%) 
GAD-7 1 (<1%) 5 (4%) 16 (13%) 26 (21%) 55 (46%) 
CFQ-R 0 2 (1%) 18 (15%) 26 (21%) 57 (47%) 
Key: CFQ-R = Cystic Fibrosis Questionnaire-Revised; DCFS = Distress in Cystic Fibrosis Scale; 
GAD-7 = Generalised Anxiety Disorder Questionnaire; PHQ-8 = Personal Health Questionnaire 
Depression Scale 
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DISCUSSION 
Overall the results suggested a one-component structure for the DCFS and provided 
support for it being an appropriate measure of distress in CF. Positive findings relating 
to internal consistency, criterion validity and participants’ feedback were found.  
However, there were potential changes to be made to improve content validity, 
specifically regarding the instructions and wording of the response scale.   
With regards to the structure, PCA indicated a five-component structure using the 
traditional Eigen value criteria.  Based on the Diabetes Distress Screening scale 
(Polonsky et al., 2005) it was possible that these components related to different aspects 
of distress, such as physical health, emotional wellbeing and social aspects.  However, 
the results were difficult to interpret meaningfully. Through further inspection of 
extraction criteria and exploratory PCA, a one-component solution was deemed most 
meaningful, with high component loadings for all items.  This is consistent with the 
purpose of the DCFS and provides support that the DCFS was measuring distress as 
intended.    
Due to this result, and the high extent of correlations between items, it could be argued 
that only one item enquiring about general distress levels is required; similar to the 
Distress Thermometer used in cancer services (Hoffman et al., 2004).  However, 
descriptive statistics demonstrated that all items were rated by participants using the full 
breadth of the ‘0-10’ scale and therefore it was deemed appropriate to retain all items.  
A further possibility was to remove any item in which only outlier data points were 
presented on the boxplots as it could be interpreted that these items are not common 
issues associated with significant distress.  However, these items were related to 
specific physical health symptoms and with the current sample being skewed towards a 
healthy outpatient population the prevalence may have been under-represented.  This is 
supported by the fact that a significant proportion of the outlier data points were 
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inpatient participants, and it would therefore be expected to see a greater representation 
of these items in future studies with higher number of inpatients.  These results provide 
support for the ‘0-10’ scale and retaining all 23 items in the DCFS.   
The DCFS was able to accurately identify on-going difficulties, similar to previously 
validated measures, with additional exploratory analyses highlighting a pattern of 
participants for whom the DCFS picks up additional distress not detected by current 
measures.  This reflects the concerns raised by clinicians in CF services and strengthens 
the rationale for having a screening tool specific to CF difficulties.  Although the DCFS 
is not intended to be used as a diagnostic tool, results suggested it was able to 
discriminate between those experiencing significant levels of depression/anxiety 
symptoms and those who are not (as measured by clinical cut-off points recommended 
for GAD-7 / PHQ-8).  It is worth noting that this difference was found in this relatively 
healthy sample.  It would be beneficial to replicate this finding in future studies with a 
larger participant pool and greater representation of those individuals experiencing high 
levels of distress.   
With regards to content validity, the development process of the DCFS suggests it 
should be sufficient, but exploratory analyses raised possible improvements to the 
wording of the response scale and instructions.  It is possible that the wording of ‘0’ as 
‘no problems’ on the visual ruler at the top of the questionnaire was confusing for 
participants, resulting in ‘0’ responses being used to indicate that that particular issue 
was not relevant to the individuals.  This also raised the possibility that individuals were 
only rating distress if the item currently applied to them.  However, the DCFS aims to 
detect distress in certain areas even if the individual is not experiencing the difficulty at 
that time.  For example, item 18 asks about an individual’s feelings about being in 
hospital; the DCFS is interested in current distress levels if the individual has been in 
hospital recently but is also interested in the individual’s feelings about potentially 
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being in hospital in future.  It is possible that this intention is not made clear in the 
instructions, resulting in individuals responding only if the item is relevant to their 
current situation.  In a clinical setting it is beneficial to discuss current difficulties and 
the distress that can be associated with particular symptoms/situations. However, it is 
also helpful to consider future problems, particularly in physical health settings such as 
CF services where there is a high likelihood of inpatient stays and deterioration in 
physical health.  Therefore, it is important to consider the wording used to ensure that 
all relevant information is being gathered so that appropriate support can be provided.   
Finally, participants’ feedback about the DCFS was positive, highlighting helpful 
aspects such as its conciseness and range of emotional difficulties addressed.  This 
provides support that it has the potential to be a clinically useful tool that patients could 
benefit from.  Suggestions were made to include comment boxes to allow individuals to 
expand on their answers.  Although this may be helpful, the purpose of the DCFS is to 
be a quick screening tool to highlight individuals for whom further assessment may be 
helpful, during which time individuals would have the opportunity to have a more 
detailed discussion about their current difficulties.   
Overall, the results demonstrated the potential of the DCFS to be an appropriate 
measure of distress in an adult CF population.  However, some changes were proposed, 
including rephrasing the instructions to emphasise that individuals should rate current 
and potential future distress in relation to items.  The wording of the visual scale was 
also changed from ‘no problems’ to ‘no concerns’ and the ‘N/A’ option removed in 
order to further reinforce that the questionnaire is asking about distress and not just 
presence of difficulties (Appendix 11, p101). 
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Limitations 
The study sample included a higher number of out-patients which may be a naturally 
healthier population in which patients are coping well with CF and are not requiring 
hospitalisation.  Consequently, this may have led to the overall distress levels in the 
study sample being skewed towards the lower end and not representative of individuals 
who experience higher levels of distress.  Additionally, the study sample also had a high 
number of participants in the ‘non-cepacia’ category.  Patients who grow cepacia or 
abscessus pathogens can be more physically unwell and therefore typically met the 
exclusion criteria of the present study.  Due to these difficulties, the generalisability of 
the study findings must be considered and it would be helpful to have a wider sample in 
future studies.    
Clinical Implications and Future Research 
The current study suggests the DCFS is a promising screening tool for detecting distress 
in an adult CF population.  It is able to detect what previously validated measures 
identify, but also identifies additional difficulties that were undetected by previous 
measures.  Furthermore, it provides helpful detail about the areas of distress specifically 
relating to CF. Participants’ feedback suggests it is an accessible tool and they value an 
opportunity to think about the emotional impact of CF.  Having a user-friendly, quick 
tool to detect these difficulties as early as possible would allow timely further 
assessment and appropriate intervention to be provided.  These initial findings of the 
utility of the DCFS are promising but recommendations have been made regarding 
possible changes.   Future research is needed to further investigate its psychometric 
properties.  Such studies should recruit a larger sample of adults with a wide range of 
current difficulties, potentially including more in-patients and those with the more 
serious pathogen growths.  Finally, in its current state, it is thought that a score of five 
or above on any item on the DCFS should prompt further assessment.  This is similar to 
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the cut-off point used in the DT in cancer services (Hoffman et al., 2004).  However, 
research should be conducted to formally explore this cut-off point for the DCFS in an 
adult CF population.   
CONCLUSION 
The current study provides support that the DCFS can be a useful measure of distress in 
an adult CF population, with positive findings related to internal consistency, criterion 
validity and participant feedback.  Potential improvements to the instructions and 
response scale were identified and subsequent recommendations made.  Future studies 
should be conducted to further investigate the psychometric properties of the revised 
tool, using a wider population.   
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APPENDICES 
Appendix 1 – Summary of Author Guidelines 
NEW SUBMISSIONS  
Submission to this journal proceeds totally online and you will be guided stepwise 
through the creation and uploading of your files. The system automatically converts 
your files to a single PDF file, which is used in the peer-review process. 
As part of the Your Paper Your Way service, you may choose to submit your 
manuscript as a single file to be used in the refereeing process. This can be a PDF file or 
a Word document, in any format or lay-out that can be used by referees to evaluate your 
manuscript. It should contain high enough quality figures for refereeing. If you prefer to 
do so, you may still provide all or some of the source files at the initial submission. 
Please note that individual figure files larger than 10 MB must be uploaded separately. 
References  
There are no strict requirements on reference formatting at submission. References can 
be in any style or format as long as the style is consistent. Where applicable, author(s) 
name(s), journal title/book title, chapter title/article title, year of publication, volume 
number/book chapter and the article number or pagination must be present. Use of DOI 
is highly encouraged. The reference style used by the journal will be applied to the 
accepted article by Elsevier at the proof stage. Note that missing data will be 
highlighted at proof stage for the author to correct. 
Formatting requirements  
There are no strict formatting requirements but all manuscripts must contain the 
essential elements needed to convey your manuscript, for example Abstract, Keywords, 
Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with 
Captions. 
If your article includes any Videos and/or other Supplementary material, this should be 
included in your initial submission for peer review purposes. 
Divide the article into clearly defined sections. 
Figures and tables embedded in text  
Please ensure the figures and the tables included in the single file are placed next to the 
relevant text in the manuscript, rather than at the bottom or the top of the file. The 
corresponding caption should be placed directly below the figure or table. 
 68 
Cover letter  
 
Corresponding authors must provide a cover letter which includes statements answering 
the following questions: 
•Has the work been seen and approved by all co-authors? 
•How is the work clinically relevant, and how does it add to existing research? 
•Have papers closely related to the submitted manuscript been published or submitted 
for publication elsewhere? If so please provide details. 
Failure to provide a cover letter addressing each of the questions above will result in the 
paper being returned to the author. The cover letter must be uploaded as a separate 
submission item. 
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Appendix 2 – Search terms 
EBSCO Host – PsychINFO, CINAHL, Psychology and Behavioural Sciences Collection 
1. Anxiety/Depression 
a. Subject headings individually per database 
b. Free text = (emotion* or wellbeing or “well being” or depress* or anxi* or 
“mental health” or mood or psycho* or distress) in title and abstract  
2. Adult 
a. Subject headings individually per database 
b. Free text = (adult or aged) in title and abstract 
3. Cystic Fibrosis 
a. Subject headings individually per database 
b. Free text = (cystic fibrosis or CF) in title and abstract 
 
OVID Host – Medline and Embase 
1. Anxiety/Depression 
a. Subject headings individually per database 
b. Free text = (emotion* or wellbeing or ‘well being’ or depress* or anxi* or 
‘mental health’ or mood or psycho* or distress).TW 
2. Adult 
a. Subject headings individually per database 
b. Free text = (adult or aged).TW 
3. CF 
a. Subject headings individually  per database 
b. Free text = (cystic fibrosis or CF).TW 
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Appendix 3 – Data Extraction and Quality Appraisal Tool 
• Article Info 
o Title, study setting, country, single centre/multicentre, method used to 
confirm CF diagnosis, sampling method 
• Sample 
o Number eligible/recruited/dropout/follow up etc,  
o Mean/SD (median/IQR) of continuous characteristics eg age, BMI, 
FEV1% 
o Frequency/proportion of categorical characteristics eg gender 
• Depression/Anxiety measures 
o What tools were used 
o Mean scores/how many presented with clinical risk 
o Definition of clinical cut off points 
• Proposed predictive factors (see list above) 
o Continuous characteristics - Mean, standard deviation (median/IQR) 
o Categorical characteristics – Frequency/proportion 
o Tools used to measure these 
• Statistical methods and effect sizes 
o Method → Bivariable or Multivariable  
o Statistical tests (effect estimate recorded):  
▪ 1. Student’s t-test (mean difference, t-statistic)  
▪ 2. Analysis of Variance (F-statistic)  
▪ 3. Pearson’s or Spearman’s correlation test (correlation 
coefficient)  
▪ 4. Simple Linear Regression (regression coefficient) 
▪ 5. Effect size (mean difference divided by pooled standard 
deviation)  
▪ 6. Multivariable Linear Regression (regression coefficient, names 
of variables included in final model)  
▪ 7. Analysis of Co-variance (F-statistic, name of variable adjusted 
for in final model)  
▪ Confounding variables accounted for? 
• Statistical significance 
o P value for each statistical test → could group into various levels… 
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reporting 
1. Were the aims/objective of the study clear?      
2. Was ethical approval or consent of 
participants attained? 
    
3. Were the methods (including statistical 
methods) sufficiently described to enable 
them to be repeated? 
    
4. Was a sample size justification, power 
description, or variance and effect estimates 
provided? 
    
5. Is it clear what was used to determine 
statistical significance and/or precision 
estimates? (eg p-values, confidence intervals) 
    
6. Were the basic data adequately described?     
7. Were the limitations of the study discussed?     
                                 Question 
Y
es
 
S
o
m
e-
w
h
a
t 
N
o
 
N
R
C
D
 
R
is
k
 o
f 
b
ia
s 
ra
ti
n
g
 
Selection 
Bias 
8. Was the study population clearly defined (is it 
clear who the research was about?) 
     
9. Was the selection process likely to select 
participants that were representative of the 
target population under investigation?  Were 
inclusion and exclusion criteria applied 
uniformly to all participants? 
    
10. Was the participation rate of eligible persons 
at least 50%? 
    
11. Were measures undertaken to address and 
categorise non-responders? 
    
Information 
Bias 
12. Was the target variable measured using 
instruments/measurements that had been 
trialled, piloted or published previously? 
(pain, QoL) 
     
13. Was the depression/anxiety variable measured 
using instruments/measurements that have 
been trialled, piloted or published previously? 
    
14. Were measures implemented consistently 
across all study participants? 
    
Confoundin
g Bias 
15. Was the study design appropriate for the 
stated aim(s)? 
     
16. Were key potential confounding variables 
measured and adjusted statistically for the 
impact on the relationship between target 
variables and psychological outcomes? Were 
any interactions between variables 
investigated? 
    
Overall 
Quality: 
 
*Not reported or cannot determine 
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Appendix 4 – Major Research Project Protocol (Version 3, 27/06/18) 
Abstract 
Cystic Fibrosis is a chronic disease with elevated risk of co-morbid anxiety and 
depression.  Current screening measures may not adequately detect distress that 
individuals with physical health conditions can experience.  
The Distress in Cystic Fibrosis Scale (DCFS) is a newly developed 23-item 
questionnaire which aims to identify areas of difficulty for adults with Cystic Fibrosis.  
This study aims to explore psychometric properties of the DCFS in an adult Cystic 
Fibrosis population.   
Approximately 115 patients with Cystic Fibrosis will be recruited.  Participants will 
complete 4 questionnaires and provide demographic information.   Analyses will be 
conducted to evaluate the reliability and validity of the DCFS.   
If found to have good psychometric properties, the DCFS could be used as an accurate 
screening tool of distress relevant to a CF population and as a regular outcome measure 
for psychological therapies in CF services.    
Introduction  
Cystic Fibrosis 
Cystic Fibrosis (CF) is an inherited, progressive and life-limiting condition in which the 
lungs and digestive system can become obstructed by thick, sticky mucus.  Despite 
recent advances in diagnosis and treatment, management of CF requires a complex, 
time-consuming daily regimen taking two to four hours, in addition to over 20 
medication tablets a day. Despite this demanding treatment routine, individuals with CF 
experience frequent infections and progressive failure of most organ systems (e.g. 
lungs, pancreas). 
Screening of psychological distress in CF  
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Various research (Smith & Schmitz, 2014; Yang et al., 2013) has shown that adults with 
chronic conditions, such as cancer and diabetes, are at higher risk for experiencing 
depression and anxiety compared to community samples. Quittner et al (2014) 
conducted an extensive study of 6088 patients with CF (The International Depression 
Epidemiological Study -TIDES) and found that depression and anxiety rates were 2-3 
times higher in individuals with CF than those reported in community samples.   
Difficulties with Current Screening Measures 
Due to financial and time constraints it is not possible to offer everyone with CF an 
annual clinical interview and therefore screening measures are routinely used to detect 
psychological distress.  The International Committee Mental Health in Cystic Fibrosis 
(ICMH-CF) advise using the Patient Health Questionnaire (PHQ-9) and Generalised 
Anxiety Disorder Questionnaire (GAD-7). However, it has been highlighted that these 
generic screens may not adequately detect psychosocial difficulties in a CF population 
as clinically ‘normal’ scores may be achieved by patients with CF for whom clinical 
assessment reveals psychosocial difficulties.  For example, patient anxieties regarding 
treatment management or attending MDT meetings may not be detected through the 
GAD-7.   Research has shown that prolonged psychological distress in patients with 
chronic illnesses can be associated with poor treatment adherence (Grenard et al, 2011), 
poor health outcomes (Riekert, 2007) and increased healthcare costs (Snell et al, 2014).   
Given these significant effects of psychological distress on quality of life and key health 
outcomes it is important that screening measures accurately detect psychological 
distress with specific reference to the physical health condition.    
Disease Specific Measures 
Disease-specific measures of emotional distress exist in other long-term conditions such 
as the Diabetes Distress Scale (DDS) (Polonsky et al., 2005) and the Distress 
Thermometer (DT) for cancer services (Hoffman et al., 2004). 
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These measures were developed due to these populations experiencing specific types of 
distress relating to their physical health conditions.  It is important to highlight that the 
term ‘distress’ is used as this is a non-stigmatizing term that describes the broad array of 
difficulties that individuals with physical health conditions can experience.  Therefore, 
the aim of these measures is not to identify psychopathology but to identify areas that 
further assessment and intervention may be beneficial ranging from physical problems 
to practical concerns.   
Distress in Cystic Fibrosis Scale (DCFS) 
The DCFS has been developed to detect distress in a CF population.  150 adult patient 
files were audited over a 3-year period to ascertain the emotional concerns CF patients 
presented with to the clinical psychologist (CP). 30 themes of psychosocial concerns 
were identified of which 8 were excluded due to being isolated occurrences (e.g. 
domestic violence and perceptual disturbance). The remaining 22 themes were included 
in the questionnaire which was constructed by adapting the framework of previously 
validated measures. It was presented to current Clinical Psychology CF outpatients 
during face-to-face contact, and was sent to the CF MDT to check face validity, with 
positive feedback received. In 2015 the questionnaire was shown to the UK 
Psychosocial Professions in CF Group (UKPP-CF) and the questionnaire format was 
improved, and one further item added. 
The final 23-item questionnaire now requires formal exploration of psychometric 
properties before the DCFS can be disseminated and used in clinical practice.     
Aims and hypotheses  
Aims  
This is the first phase to evaluate the reliability and validity of the newly-developed 
self-report measure of distress in a CF population – the DCFS.   
Hypotheses 
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• The DCFS will have acceptable psychometric properties: 
o Construct Validity: Exploratory factor analysis to determine subscales. 
o Content validity:  All 23 items on DCFS will have a score of at least 1 by 
at least 1 participant.  
o Internal consistency: The DCFS total score and subscales will have a 
Cronbach’s alpha score of above 0.7. 
o Criterion and Discriminant validity: The DCFS total score and subscales 
will have a correlation coefficient of +/-.3 with: 
▪ Total scores of PHQ-8,  
▪ Total scores of GAD-7   
▪ Total score and sub-scales of Cystic Fibrosis Questionnaire – 
Revised (CFQ-R).  
o Optimal cut-off score: DCFS total score and sub-scales will have an Area 
Under the Curve (AUC) above 0.7.  
• The DCFS will be deemed most relevant and easiest to complete by participants 
compared to the other questionnaires.   
Plan of Investigation 
Participants 
Participants will be recruited from the West of Scotland Adult Cystic Fibrosis Service 
(WoSACFS).   It has been estimated that it would be possible to gather approximately 
115 participants from in-patient wards and MDT clinics during the recruitment phase.    
Inclusion and Exclusion Criteria  
• Inclusion criteria 
o Diagnosis of CF 
o Patient attending the WoSACFS either as out-patient or in-patient  
o Aged over 18 years 
o Fluent in English 
• Exclusion criteria  
o Diagnosis of learning disability  
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o Any patient that the CF team consider too unwell due to infection 
control.  
Recruitment Procedures  
Information regarding the purpose of the study and inclusion/exclusion criteria will be 
provided to the WoSACFS.  Participants will be recruited through MDT clinics and in-
patient ward. A participant information sheet and consent form will be provided.  
Measures  
• Demographic information – Range of demographic and physical health 
measures.   
• Distress in Cystic Fibrosis Scale (DCFS) is a 23-item questionnaire.  It has an 
11-point range with endpoints labelled ‘no problems’ (0) and ‘worst I’ve ever 
felt’ (10).  Respondents are instructed to write the number (0-10) that best 
describes how they have been feeling over the past two weeks relating to each of 
the 23 items.  It takes approximately 5 minutes to complete.   
• Patient Health Questionnaire 8 (PHQ-8; Kroenke & Spitzer, 2002) is an 8-item 
self-report questionnaire, using a 4-point scale from ‘not at all’ to ‘nearly every 
day’.  Responses are based on how the individual has been feeling over the past 
two weeks.  Evidence supports reliability and validity of PHQ-8 as a measure of 
depression in the general population (Kroenke & Spitzer, 2002). It takes 
approximately 3 minutes to complete.   
• Generalised Anxiety Disorder Questionnaire -7 (GAD-7; Spitzer et al, 2006) is a 
7 item self-reported questionnaire, using a 4-point scale from ‘not at all’ to 
‘nearly every day’.  Responses are based on how the individual has been feeling 
over the past two weeks. Evidence supports reliability and validity of the GAD-7 
as a measure of anxiety in the general population (Lowe et al, 2008). It takes 
approximately 3 minutes to complete.   
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• Cystic Fibrosis Questionnaire – Revised (CFQ-R; Quittner et al, 2000) is a 50-
item disease-specific health-related qualify of life (HRQOL) measure for adults 
with CF.  There are 9 HRQOL domains; 3 symptom scales and 1 overall health 
perception scale.  The CFQ-R demonstrated robust psychometric properties and 
consistent associations with health outcomes in a large national sample (Quittner 
et al, 2012). It takes approximately 10 minutes to complete.   
• Evaluation Form – Participants will be asked which questionnaire 1) best 
described their current difficulties and 2) was the most difficult to complete.  
This will approximately take 2 minutes to complete.  
Design  
A within group design will be employed with all participants completing 4 
questionnaires.  
Research Procedures 
Potential participants will be informed about the research and given a participant 
information sheet by a familiar clinician either at their MDT meeting or during in-
patient psychology ward round.  This will be within the Queen Elizabeth University 
Hospital or West Ambulatory Care Hospital.  The research pack could be completed at 
the appointment with the researcher or at home and returned via a pre-paid envelope. 
Data Analysis  
• Descriptive stats to investigate spread of data → assessment of item inter-
correlation; mean; SD.  
• Construct Validity→ conduct an exploratory factor analysis to evaluate number 
of constructs within DCFS and determine sub-scales.  
• Content/Face Validity → is the degree to which elements of an assessment 
instrument measure what they intend to measure.  It is determined via expert 
judgement which has already been completed.  Current study could comment on 
 78 
whether all 23 items received a score of at least above 1 – this would suggest 
that the DCFS items are relevant to the wide range of distress experienced by CF 
population.   
• Internal Consistency → refers to how well the items on the DCFS relate to 
each other.  It can be tested using Cronbach’s Alpha for total score and sub-
scales of DCFS with an alpha score of >.9 indicating ‘excellent’ internal 
consistency and an alpha of 0.8-0.9 indicating ‘good’ internal consistency 
(George & Mallery, 2003).    
• Criterion/Concurrent Validity → refers to the extent to which the DCFS 
scores correlate with other validated measures.  A correlation coefficient of +/-.3 
represents a medium effect and +/-.5 represents a large effect (Field, 2013).   
• Discriminant Validity → refers to the ability of the DCFS to discriminate 
between those who experience psychological distress and those who do not. 
Cam be evaluation through correlations between items/sub-scales on DCFS and 
CFQ-R.   
• Sensitivity refers to the ability of the DCFS to correctly identify those 
experiencing psychological distress as having psychological distress; and 
specificity refers to the ability of the DCFS to correctly identify the non-
psychological distress as not having psychological distress.  Sensitivity and 
specificity can be investigated using Receiver Operator Characteristic (ROC) 
curve analysis.  Values closer to 100% represent greater sensitivity and 
specificity.  It may also be possible to identify a ‘cut off’ score using the ROC 
analysis for DCFS total score and possible sub-scales.   
• Questionnaire Evaluation →  Calculate percentages for which questionnaire 
was perceived as 1) most relevant to current difficulties and 2) most difficult to 
complete.   
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Justification of sample size  
There is limited literature guidance on sample size required for validation studies.  A 
review by Anthoine et al (2014) reported that the sample size determination for 
psychometric validation studies is rarely ever justified a priori and stated that clear and 
scientifically sound recommendations on the sample size for validation studies remains 
to be developed.  From a brief look at the literature and reviewing previous trainee 
theses, it appears that the majority of literature suggests a minimum sample size of 100 
or 5 times the number of included items.  Given this is a doctoral project with limited 
scope for recruitment, this project followed the less stringent recommendations of a 
subject-to-variables ratio of 5/1 (Anthoine, 2014).  With a 23-item questionnaire, the 
researcher aimed to recruit 115 participants.     
Settings and Equipment 
Research packs will be provided to participants within the WoSACFS as in/out-patient.   
Research packs can be completed in private rooms within WoSACFS or at home.   
Health and Safety Issues  
Infection control is imperative to consider for both researcher and participants due to the 
risk of cross infection.  The researcher will familiarise themselves with relevant health 
and safety procedures and ensure the NHS LearnPro health and safety/infection control 
module is up-to-date.   
Ethical Issues 
Ethical approval will be sought from NHS ethics and management approval from NHS 
Greater Glasgow and Clyde Research and Development committee.   
The questionnaire scores will be put into an electronic database where it will be used for 
data analysis. The anonymous data will be stored on an encrypted password protected 
University and NHS computer.  Completed paper research packs will be stored in a 
secure filing cabinet within West of Scotland Adult Cystic Fibrosis Service. My 
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supervisors (Psychologists working in West of Scotland Adult Cystic Fibrosis Service 
and Glasgow University) and I will have access to the data. Additionally, 
representatives of the study sponsor, NHS Greater Glasgow & Clyde will also require 
access if they choose to audit the study.  Personal identifiable information will be stored 
for 3 months after the end of the study, and the research data stored for 10 years.  Data 
will only be used for those purposes approved by ethics committees.  
It is possible that participants may become upset when discussing distress relating to 
their CF.  If this occurs when researcher is present, the researcher will use their skills as 
a trainee clinical psychologist to assess risk and contain any such distress.  If researcher 
has significant concerns regarding the well-being of a participant or if they score within 
clinical range on PHQ-8/GAD-7 (a score of above 10), their consent will be sought to 
pass this information to CF Team Clinical Psychologist.   Furthermore there will be 
contact information for appropriate services that the participant can utilise should they 
wish.     
All care will be taken to ensure that the potential participant is able to give informed 
consent to take part in the research.  Clear information sheets explaining the purpose 
and process of participation will be provided with the option of the researcher verbally 
reading this to the potential participant.  It will be made clear that participation is 
voluntary; participants are free to withdraw from the study at any point; and withdrawal 
from the study will have no effect on the care they receive from the WoSACFS.     
Participants will be asked to consent to a letter being sent to the West of Scotland Adult 
Cystic Fibrosis Service informing that they have agreed to participate in the study).   
Financial Issues  
Overall research cost is expected to be £131.61.     
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Timetable  
Task Estimated Time to 
Complete 
Estimated Start 
Date 
Estimated 
Completion Date 
MRP Draft 2 months 01/10/17 04/12/17 
MRP proposal 1 month 01/01/18 29/01/18 
Finalise Proposal 
and Materials 
3 months February 2018 April 2018 
Ethics Submission 3 months May 2018 August 2018 
Recruit and 
gather data 
7 months August 2018 February 2018 
Test psychometric 
properties 
2 months February 2018 April 2019 
Final write up 3 months April 2019 July 2019 
 
Practical Applications  
If the DCFS is found to be reliable and valid it can be used as a regular outcome 
measure for psychological therapies in CF services both at review meetings and during 
1-1 therapy interventions.  This will allow accurate screening of psychological distress 
relevant to their physical health condition, promote quick intervention when required 
and evaluate progress throughout therapy.  If the reliability and validity is found to be 
poor then subsequent revisions can be made to the tool and further validation studies 
conducted in the future.  
The results of the study will be written in the trainee clinical psychologist’s thesis and 
disseminated to CF centres across the UK through conferences.  Results of the study can 
also be distributed to participants who are interested in receiving them.  
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Appendix 5: Letters of Approval (REC and R&D) – original and 
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Dear Miss C Finlay, 
  
R&D Ref: GN18RM362    Ethics Ref: 18/WS/0184 
Investigator and site(s): Miss Caroline Finlay 
Project Title: Validation of a cystic fibrosis-specific measure of distress in an adult 
population 
Protocol Number: V3 
Amendment: Substantial Amendment 1 (26/11/18) 
Sponsor: NHS Greater Glasgow and Clyde 
  
I am pleased to inform you that R&D have reviewed the above study's Amendment and 
can confirm that Management Approval is still valid for this study. 
  
  
 
Reviewed Documents: 
Version 
 
Dated 
Ethics Approval Letter   05/12/18 
Notice of Substantial Amendment form   26/11/18 
Prof Jonathan Evans CV     
Dr Sejal Patel CV     
Participant Information sheet and consent form 6 11/11/18 
Updated SSI form     
  
  
I wish you every success with this research project. 
  
  
Kind regards 
  
NHS GG&C R&D 
West Glasgow Ambulatory Care Hospital 
Dalnair Street 
Glasgow G3 8SW 
  
Tel: +44 (0)141 232 1815 
Generic email for PR team: RandD.PRTeam@ggc.scot.nhs.uk 
  
Web: www.nhsggc.org.uk/r&d 
  
My working days - Mon, Tues, Thurs & Fri 7-2.30 and Wed 7-5 
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Appendix 6: DCFS Original 
Distress in Cystic Fibrosis Scale 
Below is a list of common issues affecting people with Cystic Fibrosis.  
✓ Please read each item carefully, and using the scale at the top as a guide, fill in the box next to 
each question with the number that comes closest to how you have been feeling about that issue 
over the past 2 weeks.  
✓ If a question doesn’t apply to you (e.g. for Q. 10, if you don’t have Diabetes) just write in N/A 
for ‘not applicable’.  
✓ Please don’t think over each question too much; just write the number that first comes to mind. 
 
No problems                  Worst I’ve ever felt 
 
 Over the PAST 2 WEEKS: 0...10 
1. How have you been feeling physically? 
(E.g. feeling tired, in pain, chesty, blocked up or anything else) 
 
2. H w hav  you been feeling emotionally?  
(E.g. feeling sad, worried, angry, upset or anything else) 
 
3. How have you been feeling about your work situation?  
(Whether or not you do paid work) 
 
4. How have you been feeling about your housing situation?   
5. How have you been feeling about your financial situation?  
(E.g. debts/ benefits) 
 
6. How have you been feeling about going out, socialising, or having things to 
do in the day? 
 
7. How have you been feeling about your relationships with other people? 
(E.g. your partner, friends, family or anyone else) 
 
8. How have you been feeling about managing CF treatments?  
9. How have you been feeling about your body, weight and/or eating?  
10. How have you been feeling about your Diabetes control?  
11. How have you been feeling about having a specific procedure or treatment? 
(E.g. getting a button, a port, blood tests/ needles, or anything else) 
 
12. How have you been feeling about lung function tests and results?   
13. How have you been feeling about coughing up blood (haemoptysis)?  
14. How have you been feeling about CF getting worse?  
15. How have you been feeling about a recent (new) diagnosis or bug?  
16. How have you been feeling about fertility, pregnancy or parenting?  
17. How have you been feeling about anything to do with transplant?  
(E.g. just thinking about it, being on the list, or having had one already) 
 
18. How have you been feeling about being in hospital?  
19. How have you been feeling about coming to clinic?  
20. How have you been feeling about telling other people about CF? 
 (E.g. at work, school, college or university, or friends & family) 
 
21. How have you been feeling about your use of street drugs or alcohol?  
22. How have you been feeling about upsetting past events?  
(E.g. memories of an accident, experiences as a child, a medical procedure, or 
anything else) 
 
23. How have you been feeling about anything to do with end of life? 
(E.g. Someone you know who has died, or concerns about when you die) 
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Appendix 7: Questionnaire Evaluation 
Questionnaire Evaluation 
Title of Study: Validation of a cystic fibrosis-specific measure of distress in an adult population 
 
Please answer the following questions about the questionnaires you have just 
completed. 
 
• For each questionnaire please circle how much it covered your current difficulties 
using the following scale: 
0= did not cover any of my difficulties 1= covered some of my difficulties 
2= covered most of my difficulties  3= covered all of my difficulties 
 
 
 
 
• For each questionnaire please circle how easy or difficult it was to complete with 
regards to understanding the questions and the layout, using the following scale: 
0= very difficult      1= difficult  2= Ok   3= easy 4 = very easy 
 
 
 
 Did not cover 
any of my 
difficulties 
Covered 
some of my 
difficulties 
Covered 
most of my 
difficulties 
Covered 
all of my 
difficulties 
Distress in Cystic Fibrosis Scale 
(DCFS) 
 
0 
 
1 
 
2 
 
3 
Patient Health Questionnaire 
(PHQ-8) 
 
0 
 
1 
 
2 
 
3 
Generalised Anxiety Disorder 
Questionnaire (GAD-7) 
 
0 
 
1 
 
2 
 
3 
Cystic Fibrosis Questionnaire-
Revised (CFQ-R) 
 
0 
 
1 
 
2 
 
3 
 Very 
difficult 
Difficult Ok Easy Very 
easy 
Distress in Cystic Fibrosis 
Scale (DCFS) 
 
0 
 
1 
 
2 
 
3 
 
4 
Patient Health 
Questionnaire (PHQ-8) 
 
0 
 
1 
 
2 
 
3 
 
4 
Generalised Anxiety 
Disorder Questionnaire 
(GAD-7) 
 
0 
 
1 
 
2 
 
3 
 
4 
Cystic Fibrosis 
Questionnaire-Revised 
(CFQ-R) 
 
0 
 
1 
 
2 
 
3 
 
4 
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• Please provide any other comments regarding the questionnaires that you have 
completed.  
 
 
 
 
 
 
Thank you for taking part in this study. 
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Appendix 8: Participant Information Sheet 
 
 
                      Participant Information Sheet 
Study Title: Validation of a cystic fibrosis-specific measure of distress in an adult 
population 
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it would involve for you. 
Please take time to read the following information carefully. If there is anything you 
would like to discuss, please do not hesitate to contact Caroline Finlay.   
What is the study about? 
A new questionnaire (Distress in Cystic Fibrosis Scale) has been developed to measure 
distress specific to individuals with Cystic Fibrosis.  This study looks at whether this 
new questionnaire is reliable and valid, before it can be used in an official capacity. 
This study is being completed in part fulfilment of the Doctorate in Clinical Psychology 
qualification.  
Why am I being asked to take part? 
You have been invited to take part in this study as you are supported by the West of 
Scotland Adult Cystic Fibrosis Service. 
Do I have to take part? 
No, it is up to you to decide. If you decide you do want to take part, you will get a copy 
of this information to keep and you will be asked to sign a form to show you have 
agreed to take part.  You are free to withdraw at any time, without giving reason. This 
would not affect the standard of care you receive or your future treatment. 
What would I have to do? 
You can take your time to decide about taking part in the research or not.  All 
questionnaires must be completed by March 2019 to be included.  If you decide to 
take part you would be asked to complete 4 questionnaires about your current 
distress, mood and quality of life.  Additionally, you would be asked to complete an 
evaluation form.  These questionnaires could be completed at the West of Scotland 
Adult Cystic Fibrosis Service, or at home.  It is expected to take approximately 25 
minutes in total.  The questionnaires will be reviewed by Caroline Finlay or Dr Patel as 
they may indicate some feelings of distress.  For your safety, if any risk is identified, 
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such as high levels of anxiety or low mood, this information will be passed onto Dr 
Patel, Clinical Psychologist for the West of Scotland Adult Cystic Fibrosis Service.  
You will also be asked to give permission for Caroline Finlay to access your medical 
records within the West of Scotland Adult Cystic Fibrosis Service to gather recent 
physical health measurements including weight and lung functioning, and classification 
of CF.   
Who else would know I am doing this? 
The staff at the West of Scotland Adult Cystic Fibrosis Service will be informed that you 
are taking part in the study, but all the information that you provide will be kept 
confidential. All data collected will be anonymised in the research report. 
Confidentiality will only have to be broken if there were concerns that you or someone 
else was at risk of harm. If this happened then the information will be passed onto Dr 
Patel, Clinical Psychologist for the West of Scotland Adult Cystic Fibrosis Service.  
What happens to the information? 
NHS Greater Glasgow and Clyde (NHS GG&C) is the sponsor for this study based in the 
United Kingdom.  We will be using information from you and your medical records in 
order to undertake this study and will act as the data controller for this study.  This 
means that we are responsible for looking after your information and using it properly. 
NHS Greater Glasgow and Clyde will keep identifiable information about you for 3 
months after the study has finished.   
Your rights to access, change or move your information are limited, as we need to 
manage your information in specific ways in order for the research to be reliable and 
accurate.  If you withdraw from the study, we will keep the information about that we 
have already obtained.  To safeguard your rights, we will use the minimum personally-
identifiable information possible.   
For the current study the questionnaire scores will be put into an electronic database 
where it will be used for data analysis. The anonymous data will be stored on an 
encrypted password protected University and NHS computer.  Completed paper 
research packs will be stored in a secure filing cabinet within West of Scotland Adult 
Cystic Fibrosis Service. My supervisors (Psychologists working in West of Scotland Adult 
Cystic Fibrosis Service and Glasgow University) and I will have access to the data. The 
information will be analysed and presented in the form of a report and submitted to 
the University of Glasgow in part fulfilment of the Doctorate in Clinical Psychology, for 
publication in a scientific journal, and at relevant conference presentations. All 
participants will be provided with a summary of results if they would like them. 
NHS GG&C will use your name, NHS number and contact details to make sure that 
relevant information about the study is recorded for your care, and to oversee the 
quality of the study.  Individuals from NHS GG&C and regulatory organisations may 
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look at your medical and research records to check the accuracy of the research study.  
The research team will pass these details to NHS GG&C along with the information 
collected from you and your medical records.  The only people in NHS GG&C who will 
have access to information that identifies you will be the people who need to audit the 
data collection process.  The analysed data will not contain any personal identifiable 
information.   
NHS GG&C will collect information about you for this study from medical records and 
the questionnaires you complete.  This information will include your name, NHS 
number, contact details and health information, which is regarded as a special 
category of information.  We will use this information to audit the research project.   
You can find out more about how we use your information from the contact details 
below. 
What are the possible benefits and risks of taking part? 
Current measures of distress do not always identify the specific distress experienced 
by individuals with Cystic Fibrosis.  Specific measures of distress have been developed 
for other health conditions such as cancer and diabetes. By taking part in this research 
you will be contributing to the development of a new questionnaire measuring distress 
specifically related to Cystic Fibrosis.   
The questionnaires asking about your distress and mood may highlight that you are 
having some difficulties with your emotional wellbeing.  You are free to withdraw from 
the research at any time and can access psychological support within the West of 
Scotland Adult Cystic Fibrosis Service.   
Who has reviewed the study? 
This study has been approved by the University of Glasgow, the West of Scotland 
Research Ethics Committee and the NHS Greater Glasgow & Clyde Research and 
Development Team. 
Who do I contact for more information? 
You may contact any of the researchers involved in this study if you have further 
questions about the research. An independent contact person is also available to 
provide information about taking part in research. Contact details can be found at the 
end of this leaflet. 
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What do I do now? 
If you are interested in taking part in the research then please: 
• Complete the consent form, the four questionnaires, and the evaluation form 
in the research pack.  The completed research pack can be handed back to 
Caroline Finlay or Dr Sejal Patel.   
• Alternatively, if you would prefer to complete the questionnaires at home, 
please do so and post the completed research pack using the pre-paid 
envelope provided.   
 
What if I have a complaint? 
If you have any problems during the study, please do not hesitate to contact any 
member of the research team (contact information below). 
If you wish to make a formal complaint, please contact: 
Complaints Department 
West Glasgow Ambulatory Care Hospital 
Dalnair Street 
Glasgow 
G3 8SJ 
Phone: 0141 201 4500 
Email: complaints@ggc.scot.nhs.uk 
 
Thank you for taking the time to read this leaflet and for any further input you may 
wish to have. 
 
Contact Information: 
Name Role Email Telephone 
Caroline Finlay Researcher c.finlay.2@research.gla.ac.uk  
Dr Alison 
Jackson 
Academic 
Supervisor 
Alison.Jackson@glasgow.ac.uk 0141 211 3917 
Dr Sejal Patel Clinical 
Supervisor 
sejal.patel@ggc.scot.nhs.uk  
Rory O’Connor Independent 
Contact 
Rory.OConnor@glasgow.ac.uk  
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Appendix 9: Participant Consent Form 
 
         Consent Form 
 
Participant ID Number: ____________ 
Title of Study: Validation of a cystic fibrosis-specific measure of distress in an adult population 
Name of Researcher: Caroline Finlay (Trainee Clinical Psychologist) 
         Please initial each box. 
 
I confirm that I have read and understood the Participant Information Leaflet (Version 5, 
17/10/18) for the above study and have had the opportunity to ask questions.   
 
I understand that my participation is voluntary and that I am free to withdraw at any time 
and without giving any reason.  If I do withdraw from the study my continued care will not 
be affected. 
 
I understand that my medical care or legal rights will not be affected by taking part.  
 
I understand that Caroline Finlay and supervising Psychologists (Dr Alison Jackson, University 
of Glasgow and Dr Sejal Patel, West of Scotland Adult Cystic Fibrosis Service) will have 
access to the information that I provide. My information may also be looked at by 
representatives of the study Sponsor, NHS GG&C, for audit purposes. 
 
I understand that Caroline Finlay will contact Dr Patel if any risk is identified from the 
questionnaires.  
 
I give permission for the researcher to inform the West of Scotland Adult Cystic Fibrosis 
Service of my involvement in this study.   
 
I give permission for the researcher to access my medical records held within the West of 
Scotland Adult Cystic Fibrosis Service.  
 
I would like to receive a summary of the project findings once it is completed (estimated 
completion date December 2019). Please send a copy to me at the following address: 
 
 
I agree to take part in the above study. 
________________________________   _________        _______________ 
Name of Participant     Date  Signature  
 
________________________________   ________ _____________ 
Name of Researcher     Date  Signature 
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Appendix 10: N (%) of participant responses to DCFS items   
DCFS 
Question 
Median 
(IQR) 
N (%) 
scoring 
‘N/A’  
N (%) 
scoring ‘0’ 
N (%) 
scoring 1-4 
N (%) 
scoring 5-10 
1 3 (5) 0 19 (16) 54 (45.4) 46 (38.6) 
2 3 (5) 0 32 (26.9) 51 (42.9) 36 (30.2) 
3 1 (5) 8 (6.7) 44 (37) 39 (32.8) 28 (23.5) 
4 0 (2) 0 81 (68.1) 23 (19.3) 15 (12.6) 
5 1 (4) 0 58 (48.7) 35 (29.4) 26 (21.9) 
6 1 (4) 0 56 (47.1) 35 (29.4) 28 (23.5) 
7 0 (4) 0 62 (52.1) 31 (26) 26 (21.9) 
8 1 (4) 0 49 (41.2) 44 (37) 26 (21.8) 
9 2 (5) 0 42 (35.3) 40 (33.6) 37 (31.1) 
10 0 (2) 44 (37) 50 (42) 14 (11.8) 11 (9.2) 
11 0 (2) 13 (10.9) 74 (62.2) 16 (13.5) 16 (13.4) 
12 1 (3) 1 (.8) 58 (48.7) 41 (34.5) 19 (16) 
13 0 (0) 22 (18.5) 77 (64.7) 13 (10.9) 7 (5.9) 
14 2 (5) 1 (.8) 42 (35.3) 44 (37) 32 (26.9) 
15 0 (0) 15 (12.6) 80 (67.2) 12 (10.1) 12 (10.1) 
16 0 (3) 8 (6.7) 63 (52.9) 31 (26.1) 17 (14.3) 
17 0 (0) 13 (10.9) 82 (68.9) 14 (11.8) 10 (8.4) 
18 0 (4) 8 (6.7) 60 (50.4) 25 (21) 26 (21.9) 
19 0 (2) 1 (.8) 70 (58.8) 34 (28.6) 14 (11.8) 
20 0 (2) 0 76 (63.9) 23 (19.3) 20 (16.8) 
21 0 (0) 13 (10.9) 92 (77.3) 8 (6.7) 6 (5.1) 
22 0 (3) 1 (.8) 73 (61.3) 21 (17.7) 24 (20.2) 
23 0 (4) 0 68 (57.1) 23 (19.3) 28 (23.6) 
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Appendix 11: Proposed Revised DCFS 
Distress in Cystic Fibrosis Scale (DCFS) 
 
Below is a list of common issues that affect many people with CF. They may or may not all 
affect you now, or in the future. We are still interested in how you feel about them.  
✓ Please read each item carefully, and using the scale at the top as a guide, fill in the box 
next to each question with the number that comes closest to how you have been feeling 
about that issue over the past 2 weeks.  
✓ Please don’t think over each question for more than a few seconds; just write in the first 
number that comes to mind. 
 
 No concerns                              Worst I’ve ever felt 
 Over the PAST 2 WEEKS: 0...10 
1. How have you been feeling physically? 
(E.g. feeling tired, in pain, chesty, blocked up or anything else) 
 
2. How have you been feeling emotionally?  
(E.g. feeling sad, worried, angry, upset or anything else) 
 
3. How have you been feeling about your work situation?  
(Whether or not you do paid work) 
 
4. How have you been feeling about your housing situation?   
5. How have you been feeling about your financial situation?  
(E.g. debts/ benefits) 
 
6. How have you been feeling about going out, socialising, or having things to do in 
the day? 
 
7. How have you been feeling about your relationships with other people? 
(E.g. your partner, friends, family or anyone else) 
 
8. How have you been feeling about managing CF treatments?  
9. How have you been feeling about your body, weight and/or eating?  
10. How have you been feeling about CF-related diabetes (CFRD)? 
(Either now, or as a potential future possibility) 
 
11. How have you been feeling about having a specific procedure or treatment? 
(E.g. getting a button, a port, blood tests/ needles, or anything else) 
 
12. How have you been feeling about lung function tests and results?   
13. How have you been feeling about coughing up blood (haemoptysis)? 
(Either now, or as a potential future possibility) 
 
14. How have you been feeling about CF getting worse?  
15. How have you been feeling about a recent (new) diagnosis or bug?  
16. How have you been feeling about fertility, pregnancy or parenting?  
17. How have you been feeling about anything to do with transplant?  
(E.g. just thinking about it, being on the list, or having had one already) 
 
18. How have you been feeling about being in hospital? 
(Either now, or as a potential future possibility) 
 
19. How have you been feeling about coming to clinic?  
20. How have you been feeling about telling other people about CF? 
 (E.g. at work, school, college or university, or friends & family) 
 
21. How have you been feeling about using street drugs or alcohol?  
22. How have you been feeling about upsetting past events?  
(E.g. memories of an accident, experiences as a child, a medical procedure, or 
anything else) 
 
23. How have you been feeling about anything to do with end of life? 
(E.g. Someone you know who has died, or concerns about when you die) 
 
 
